reason report
question manag
bottom line host seventh annual global healthcar
confer februari analyst compos
list question tailor manag team
meet manag listen present
next day think find answer question
help gain invest edg current market
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
februari edt rx trend deriv im health
analyst daniel antalffi medic suppli devic
long-term growth outlook manag see sustain growth trajectori anoth indic come line size high risk percutan
coronari intervent pci cardiogen shock market opportun
cardiogen shock saw nice uptick cardiogen shock growth recent quarter y/i growth much attribut
intern focu train data time vs call arm saw tct late octob
high risk pci tailwind drive high risk pci growth continu strong double-digit rang continu momentum complex high risk pci chip
japan/intern alreadi seem track slightli ahead japan least center add perspect think drive faster adopt
frame view growth trajectori ultim market opportun
pipelin come pipelin could drive increment adopt and/or expand indic pipelin contribut long-term sale
vision
impella stemi trial enrol progress studi expect complet
optic sensor impella cp fda approv launch
impella japan launch treat first japanes patient late octob control
commerci roll-out expect hospit end march
ecp expand cardiac power first-in-man ecp expect
impella ce mark expect
impella btr bridg recoveri tbd
short interest float
attende andrea pfeifer ceo joerg hornstein cfo lisa sher head ir
rate aria- crenezumab much lower observ antibodi also target oligom plaqu implic
respect crenezumab interpret aducanumab phase data word would success failur impli confid level
program
multipl anti-tau antibodi clinic develop antibodi compar other mp op etc relev attribut
rel beta-amyloid tau believ contribut alzheim diseas process
multipl compani work abeta vaccin past limit success challeng encount compani work area
ac immun hypothesi differ
short interest float
see luspatercept profil compar hypoxia induc factor hif inhibitor also phase trial myelodysplast syndrom md
realist luspatercept compet gener erythropoiesis-stimul agent esa front-lin treatment md
might investor see result luspatercept myelofibrosi monotherapi post jakafi combin therapi jakafi bigger opportun
differ forese price strategi md beta thalassemia myelofibrosi
function endpoint trial might form basi approv
differ
initi phase command trial md
phase believ trial result beta thalassemia
phase medalist trial result md
begin phase ii studi sotatercept pulmonari arteri hypertens
short interest float
summar clinic benefit demonstr phase trial edsivo vascular ehlers-danlo syndrome/v
opportun urea cycl disord mapl syrup urin diseas
data fda want see order approv candid
plan set commerci organ pre-commerci work done support market uptak edsivo
intellectu properti protect edsivo
nda file edsivo vascular ehlers-danlo syndrome/v
nda file urea cycl disorder/ucd mapl syrup urin disease/msud
short interest float
plazomicin respect spectrum activ clinic data carbapenem-resist enterobacteriacea safeti compar agn op avycaz
updat incid data tell market today recent growth rate
expect obtain data plazo label import launch strategi
think plazomicin could fit urinari tract infect uti standard care
expect clinical/regulatori path c-scape
short interest float
make target complement factor cfd attract complement mediat diseas advantag inhibit cfd paramet
import cfd vs inhibitor altern meaning cfd vs inhibitor
consid cfd inhibitor target differ part complement pathway alxn soliri inhibitor translat clinic result
differ could see demonstr efficaci paroxysm nocturn hemoglobinuria pnh
parallel develop convers clinician fda gone far
next-gen cfd inhibitor improv think translat market
search achn new go see achn move differ direct get new compani impact
interim data updat pnh
initi pnh among partial respond soliri
initi open-label studi initi poc trial
interim data next-gen cfd inhibitor
earli encourag data link medacorp kol check suggest pnh bear watch link
short interest float
analyst seamu fernandez
commerci launch eskata hydrogen peroxid seborrh keratosi sk progress discuss strategi promot effort
phase data common wart certainli merit drug move phase despit uniqu opportun provid differenti treatment tough treat
condit investor interest seem limit date market miss
multipl oral jak program develop discuss topic program alopecia areata plan differenti approach
pursu like see on-going topic studi read balanc might see proof princip data topic jak androgenet
jak inhibitor safeti top mind last month oral program potl competitor treatment sever alopecia areata face fda delay due dose
concern rheumatoid arthriti safeti question pan-jak inhibitor indic ulcer coliti first topic jak effort avoid safeti
concern plan progress oral jak inhibitor compound limit regulatori challeng
discuss jak opportun vitiligo mechanist rational like condit treat topic jak
top-line data us ph alopecia areata aa studi patient one month durat ati-
topic jak inhibitor
top-line data australia ph eyebrow studi patient
initi phase dose rang studi aa
end phase fda meet common wart
top-line data proof-of-concept ph studi pts- drug
initi phase common wart program
short interest float
drug devic combo histor lower approv odd and/or longer review cycl degre view inbrija parkinson nda
similar risk profil
speak manufactur system surround inbrija rtf request file question fda rais around chemistri manufactur control
address
youv talk peak sale potenti inbrija least assumpt go price patient volum
think price inbrija sort assumpt need make regard product price ration exampl think
averag frequenc use
mention wsj explor potenti sale think busi develop compani build go forward
inbrija fda accept nda file feb
short interest float
attende greg went chairman ceo founder alf merriweath cfo
speak assumpt behind guidanc term patient treat sale sort recept observ physician
commerci model your employ compar specialti franchis like comparison what uniqu admss
public suggest efficaci ir amantadin wane time myth true comparison seen gocovri
speak amantadin may work ms walk exactli mechan amantadin similar/differ mematin doesnt benefit fatigu
actual worsen neurolog symptom ms
provid overview rational behind statu program big would superior studi base
know vimpat popul your pursu increas exposur think advers event risk
fda end meet
short interest float
tcr compar car-t key opportun tcr
much physician educ necessari t-cell therapi becom viabl commerci product solid tumor indic
adap tcr platform technolog differenti vs tcr platform space
provid updat progress made term manufactur capabl
investor expect updat proprietari tcr program afp
multipl tcr phase i/ii data present
short interest float
analyst seamu fernandez
regard phase monotherapi trial sting agonist data expect second half year regard patient number follow-up
develop plan differ sting agonist op mp well intratumor approach tlr
agonist oncolyt virus
expect efficaci data combo nv mp inhibitor
respect potenti advantag target proliferation-induc ligand april b-cell matur antigen bcma ultim
expect agent fit increasingli crowd multipl myeloma treatment paradigm
view prospect overal listeria platform person live attenu double-delet ladd vaccin partnership janssen
op given recent discontinu ladd vaccin target mesothelioma
sting agonist monotherapi report dose escal portion phase studi
antibodi discuss preliminari observ
anti-april antibodi publish preclin data
report preliminari phase biomark observ
antibodi initi phase studi
short interest float
much safeti efficaci data gener coversin pnh date clinic pictur would say emerg
challeng expect enrol phase studi pnh horizon
coversin efficaci compar
much conveni advantag daili subcutan inject sq versu less frequent iv administr alxn antibodi
statu longer-act version coversin
initi coversin pnh
initi coversin dual leukotrien bullou pemphigoid
initi coversin dual leukotrien atop keratoconjunctivitis/akc
initi once-weekli coversin la
akari seek address sub-optimal treatment benefit soliri coversin link
short interest float
attende randi schatzmann ceo elisabeth sandov evp corpor
two phase iii complet result eptinezumab differ cgrp calcitonin gene-rel peptid antibodi view
expect see year alder respect eptinezumab long term safeti updat knowledg new issu manifest
increas immunogen come upon repeat dose
think launch strategi eptinezumab mani rep expect need us plan partner outsid us
think potenti competit oral cgrp prevent set
last year mention go pursu subq administr follow-on inject program dose explor phase ii test
quarterli what next readout/upd
iv eptinezumab complet open label safeti studi
short interest float
attende paul clanci cfo john orloff head catherin hu
earli commerci dynam patient seek treatment patient initi soliri myasthenia gravi launch indic time
like phase treatment-nav result show superior soliri usual rate lactat dehydrogenas ldh normal soliri
analysi two co-primari endpoint work like rate transfus requir soliri treat patient
greater safeti risk meningococc infect compar soliri mani meningococc infect seen
background rate seen cumul clinic experi soliri
clinic trial requir bring subcutan version market iv formul success approv
complement-medi diseas would suitabl subcutan regimen explor approv
long much soliri impact growth headwind trial competitor trial subcutan develop
compani strategi busi develop includ transact type size asset stage therapeut area
phase paroxysm nocturn hemoglobinuria pnh treatment-nav soliri
short interest float
growth driver behind rev/cas start guidanc call upper-end lt growth goal guidanc factor impact potenti
new competit clear align categori quantifi
management prepar re-evalu market light potenti increas competit would management highlight algn key competit
advantages/barri entri management think potenti increment price pressur categori new entrant come marketplac
fallout dissatisfact see orthodont rank follow smiledirectclub sdc invest stake could potenti make orthodontist
amen trial/work competitor align product
take definit identify/cal inflect point us teen adopt increment teen/dtc market spend direct compar
spent take drive increas teen penetr gp channel management see earli sign acceler uptak segment yet
kind spend reinvest busi investor think long-term strategi store pilot program
give management confid fda approv time mandibular advanc kind addit data collect request fda much
management estim algn share scanner market penetr segment whole potenti market opportun
chicago midwint dental meet feb meet histor
forum new product launch clinic present
potenti competit launch
mandibular advanc fda approv expect
short interest float
analyst seamu fernandez
pleas discuss detail esmya updat european agenc youv express great deal confid safeti esmya continu despit
concern rais liver safeti give much confid despit updat fda reach concern provid
fda support file speak broader import esmya overal women health franchis
despit extens around safeti efficaci ubrogep phase top-lin result recent confer call still seem confus
concern around efficaci liver safeti compound miss efficaci benefit ubrogep product uniqu posit benefit
patient triptan non-respond discuss five case elev liver enzym ubrogep confound issu might result vs placebo
compar liver safeti data over-the-counter nsaid
vraylar continu come initi expect recent deliv posit phase result bipolar depress differenti vraylar clinic
might bring treatment bipolar depress updat neg symptom fda hope approach futur label updat
clinic data section label indic
phase abicipar data approach late success look like view point efficaci safeti standpoint
hope deliv follow mid- late-stag program specif atogep rapastinel push rapastinel oral relamorelin
profil hope deliv patient
top-lin phase atogep migrain prevent data
result second phase studi ubrogep acut migrain
pdufa esmya
top-lin phase abicipar retin diseas data
short interest float
potenti breadth patisiran label inclus cardiac diseas impact think patisiran price
breadth patisiran label impact think develop ttrsc
think approv path ttrsc plan explor acceler path hattr use ttr lower surrog endpoint
wild-typ diseas see on-going mp tafamidi trial proxi program ttrsc could look like
givosiran phase i/ii look like baselin attack frequenc lower sequenti cohort think baselin attack frequenc ahp
phase versu seen phase i/ii lower expect baselin attack frequenc reason interim analysi includ output
increas studi
beyond patisiran givosiran fitusiran what next major program
short interest float
vascepa prescript grade fish-oil product current use physician
reduce-it outcom studi result expect success would open larg opportun growth would defin success studi
discuss exist clinic literatur clinic data may give us visibl potenti outcom reduce-it studi
broad possibl outcom reduce-it studi would impact commerci strategi
see compani head next year expect compani focu beyond vascepa
final patient studi visit reduce-it studi start march
reduce-it cardiovascular outcom studi statin treat patient persist elev
tgs- top line end
potenti expans amarin sale forc post reduce-it trial
short interest float
although perform growth product remain strong clear legaci product face increas pressur next year amgen return
growth current portfolio
maintain recent strong margin perform product mix shift toward biosimilar partner product erenumab tezepelumab etc
big busi develop war chest focu compani busi develop ambit
compani recent comment suggest compani re-direct effort away oncolog toward primari care indic
requir primari care categori achiev widespread reimburs signific adopt commerci success price elast chang
us approv blincyto acut lymphoblast leukemia mrd-posit
us approv aimovig migrain prevent
phase data abp rheumatoid arthriti
us/eu approv kyproli myeloma base endeavor data
short interest float
would character galafold fabri diseas launch thu far patient mix treatment-experienc ert-switch treatment-nav
shown across cohort pomp diseas studi
penciled-in meet fda investor expect updat
made decid pursu observ studi pomp diseas
remind us manufactur capac particularli compar materi gener mani patient address current scale
regulatori decis migalastat fabri diseas japan
regulatori updat
potenti fda approv migalastat
initi pivot studi
promis pomp data link migalastat nda submit link
short interest float
leadership trial could use background pain medic impact result control
see maximum daili pain better clinic measur averag daili pain interstiti cystiti ic patient level subject experi
evalu one versu differ less variabl opinion
power phase studi statist hurdl align hurdl clinic meaning
challeng diagnos bladder pain/ic control phase
degre studi align commentari emerg recent bone reproduct urolog drug advisori committe meet
short interest float
analyst seamu fernandez
youv guid peak sale tenapanor hyperphosphatemia could walk assumpt drive peak sale estim
view would defin success efficaci standpoint second phase trial tenapanor would replic mean reduct seen
first phase view success
see shift prescrib pattern beyond expect impact brand renvela chang strategi think opportun
tenapanor price commerci launch strategi dialysi bundl impact
constip predomin irrit bowel syndrom ibs-c tenapanor differ trulanc novel mechan chang prescrib habit
physician new mechan help dialogu payer manag care convey differ physician payer
program potassium secretagogu hyperkalemia differ identifi reason serum bicarbon effect saw
onset action studi
fling nda tenapanor constip
readout second phase end stage renal diseas esrd patient expect
addit partnership licens deal throughout
short interest float
recap saw ralinepag studi pulmonari arteri hypertension/pah compar selexipag data
propos studi exercis toler outcom head-to-head align object
ahead moderate-to-sever ulcer coliti uc data walk us trial design ozanimod touchston experi aid amend
uc data posit think commerci plan
also guid data pain associ crohn diseas cd hope show trial
etrasimod data moderate-to-sever ulcer coliti uc
data pain associ crohn diseas cd
regulatori updat trial design ralinepag pulmonari arteri hypertens
trial enrol updat etrasimod primari biliari cholang pbc pyoderma
short interest float
posit ralinepag data pah link etrasimod uc data preview link kol event highlight broad applic etrasimod link
market oppti line icca percentag line icca patient known gene fusion kind therapi durat expect base
data far
posit icca rel compet fgfr agent develop incyt
high bar expand line treatment option icca label extens
btk inhibitor differenti ibrutinib next gen agent develop percentag btk-inhibitor treat patient
learn upcom phase ia data
btk cell malign ph data
akt inhibitor oncolog ph biomarker-driven data expect
fgfr icca fgfr ph interim updat
short interest float
pdufa date binimetinib/encorafenib braf melanoma come june talk pre-launch activ confid level captur
share market
braf/mek inhibitor could use adjuv melanoma set well base recent data nv high bar get binimetinib/encorafenib compendia list
adjuv melanoma
beacon-crc phase trial braf colorect cancer compani talk potenti amend trial design incorpor efficaci interim analysi
talk differ consider amend trial design potenti timelin potenti interim analysi
plan address front-lin patient potenti trial may need run get front-lin label import egfr inhibitor
mix
lot interest combin mek inhibitor checkpoint inhibitor patient independ braf statu talk partner strategi area
current posit rel other
selumetinib azn thyroid cancer top-lin data pivot trial
binimetinib/encorafenib braf melanoma pdufa june
encorafenib braf colorect cancer ph beacon top-lin data expect
short interest float
could recap saw transcon growth hormon program latest updat data investor expect see
timelin ex-u plan growth hormon program
see recent data readout transcon parathyroid hormon pth hypoparathyroid strategi move directli
consid natpara sale fallen short expect strategi maxim market penetr
transcon c-type natriuret peptid compar bmrn vosoritid achondroplasia endpoint expect
height data transcon growth hormon
flight switch trial enrol complet transcon growth hormon
full data transcon pth hypoparathyroid
ph initi transcon c-type natriuret peptide/cnp achondroplasia
top-lin data transcon achondroplasia
short interest float
posit asnd heel disappoint vsar nr data link transcon pth deliv top-lin data anticip link
uniqu rel core protein alloster modifi cpam develop today
level antigen reduct consid meaning competit therapi develop op hurdl vari
look preclin data impli regard rel potenc molecul compet strategi
beyond phase ii think registr path term overal number studi patient treat efficaci endpoint durat exposur etc
follow similar develop path
initi phase iia proof concept poc studi
short interest float
mitchel chan director north america
analyst seamu fernandez
given posit top-lin data bmi op trial opdivo nivolumab yervoy ipilimumab first-lin non-smal cell lung cancer
nsclc plan pursu use tumor mutat burden tmb biomark imfinzi durvalumab tremelimumab either
mystic anoth trial
view market imfinzi stage unresect nsclc beyond larg opportun immuno-oncolog io adjuv treatment earli
stage cancer across tumor type well azn pois captur share market
broad opportun lynparza olaparib parp inhibitor beyond breast ovarian cancer parp inhibitor combin io vegf inhibitor
endocrin therapi dna damag respons approach find intrigu see initi opportun
might see initi data calquenc acalabrutinib btk inhibitor chronic lymphocyt leukemia cll believ agent differenti
mp jnj op imbruvica ibrutinib
see sever asthma market evolv launch fasenra benralizumab think eventu competit dynam
tezepeluamb anti-tslp given partnership mp
think market opportun agent roxadustat hif-ph inhibitor unmet need believ agent potl deliv
dialysi non-dialysi chronic kidney diseas ckd market kind safeti profil believ necessari succeed might differ region region
pdufa tagrisso osimertinib egfr inhibitor first-lin egfrmut non-smal cell lung cancer
nsclc
pdufa imfinzi stage unresect nsclc
top-lin result arctic trial imfinzi third-lin nsclc
overal surviv os result mystic trial imfinzi tremelimumab first-lin nsclc
top-lin result trial lynparza first-lin ovarian cancer mainten
short interest float
recap saw initi aspiro cohort x-link myotubular myopathy/xlmtm compar healthi children natur histori
initi aspiro data exceed intern expect think higher dose vg/kg stage pursu
plan meet regul possibl acceler regulatori path
hope show preliminari valen data crigler-najjar syndrome/cn
step remain ind equival file pomp diseas catecholaminerg polymorph ventricular tachycardia/cpvt
ind/cta file catecholaminerg polymorph ventricular tachycardia/cpvt
aspiro data updat x-link myotubular myopathy/xlmtm
valen prelminari data crigler-najjar syndrome/cn
ind file pomp diseas
initi link promis preliminari data link
short interest float
remind us aurora trial design evalu voclosporin lupu nephriti ln compar similar patient demograph trial site
endpoint aura studi
thu far rate patient drop-out sever advers event and/or death aurora trial compar aura studi
aurinia previous state submit modul nda ln explain us compon modul well put context
signific progress ln program
contempl expand renal franchis fsgs/mcd focal segment glomerulosclerosis/minim chang diseas met regul determin
voclosporin differenti exist dri eye syndrom de therapi restasi xiidra shpg would voclosporin mechan action
calcineurin inhibitor cni valu ad de patient compar exist therapi
interim ph data readout fsg
top-lin ph data readout de
submiss modul ln nda
short interest float
enrol complet ln trial set voclosporin franchis expand de link
tivozanib differenti tki alreadi approv treatment rcc
tivozanib met primari endpoint orr compar sorafenib phase trial neg trend os os differ interpret
cross-ov alon certainti
assumpt underli trial design term perform control treatment arm basi assumpt
assum posit big market opportun rcc view
phase data present asco-gu combin tivozaniv opdivo key takeaway form studi next step combin program
tivozanib renal cell carcinoma line ph data
tivozanib renal cell carcinoma opdivo ph ii tinivo updat data
short interest float
key driver behind management least revenue growth guidanc revenu growth depend break middle-adopt segment
still achiev relianc pure earli adopt segment extent breast reconstruct neurot brn revenu contribut contempl management
growth outlook management achiev growth even without brn contribut increas penetr exist trauma market alon
give management confid sustain beyond trend rang multipl year would caus
drop realist timelin turn profit
management anticip initi target site brn mani site current run kind earli feedback pushback
receiv initi experi new applic much invest requir implement market develop activ around new segment
educ program sale forc doc train build consum awar kind direct-to-consum dtc initi pilot educ breast
reconstruct patient breast neurot use avanc
initi procedur area compani like target treatment iatrogen pain right way think launch cadenc phase
approach differ surgic applic sequenti broad indic varieti procedur mgmt estim broader iatrogen pain opportun
factor differ etiolog
investor think new rep addit long-term pay-off hire long take rep becom fulli product fulli
product rep gener annual basi average
recon studi phase trial support transit avanc nerv graft licens biolog
expect complet enrol
breast reconstruct neurot brn dual vs singl neurot studi expect
complet enrol
sensation-now ranger registri studi autolog bnr expect enrol center
axoguard nerv cap studi studi evalu management symptomat neuroma vs neurectomi
expect complet enrol
short interest float
earn call schedul pm
analyst daniel antalffi medic suppli devic
posit leverage/ep growth pushback post-quart seem mild disappoint around oper margin expans guidanc
walk us headwind impact guidanc run rate actual ex headwind integr clari
begun realiz meaning sale oper synergi think sustain level annual margin expansion/ep growth out-year
see sustain double-digit ep grower long-term
near-term outlook number headwind impact oper sale growth least includ hurrican impact ex headwind
think bax underli oper sale growth rate headwind tailwind consid specif across
busi clari cyclo what real likelihood goe off-pat iv therapi move mexico
long-term outlook look across bax suit busi end-us market growth bax competit posit product pipelin base portfolio
today right sustain long-term sale growth outlook get sale growth
capit deploy tax reform what latest priorit potenti capit deploy
portfolio optim constantli evalu portfolio metric use decid whether busi product line continu fit within bax long-term
point-of-car solut periton dialysi pd expect start clinic trial
launch product
hdx expand hemodialysi therapi enabl theranova trial enrol patient
launch expect
oxiri label expans oxiri label expans took effect countri
europ well geographi middl east africa global roll-out on-go
short interest float
becton dickinson compani market perform
potenti area upsid could lead higher-than-guid lsd hsd bcr ep accret target key cost save bucket
rough time compris management cumul synergi target compar contrast bcr synergi vs carefus cfn synergi -- -where
bigger opportunities/challeng vs cfn integr think time potenti revenue synergi biggest near/long-term opportun
management see growth rest play cadenc perspect given newco guidanc impli pretti signific growth acceler
get full-year potenti contd tailwind stronger-than-anticip flu season factor growth acceler
commit de-lever management given current gross leverag ratio compani see ratio get next month
investor think bdx appetit kind debt pay key cash prioriti
msd growth rate sustainable/reason expect medic manag solut busi go forward normalized/underli basi recal
although declin y/i report basi underli growth -- -i adj us dispens acctg chg tough y/i comp -- -wa kind market share
assumpt would necessari increas presum sustain type growth dispens infus pump posit market share
gain perspect market
lever balanc sheet deploy new product management give confid off-set gore royalti goe away late
lutonix av access indication/launch progress kind revenue contribution/penetr market opportun expect beyond big
ww av access market oppti regard lutonix below-the-kne btk indic investor expect see first read lutonix btk trial follow-
confer investor plan term clinic present assum pma submiss year-end reason assum lutonix btk
indic launch much would btk increas lutonix tam
new iv solut offer expect includ sodium chlorid dextros
lutonix below-the-kne btk trial follow-up result pma submiss expect
covera stent graft av access graft indic us approv expect year-end
bd menu expans enter viral panel tb assay expect
bd onclar hpv assay approv expect
proseri lifest platform us launch next month
smart type diabet patch pump launch expect year-end
short interest float
competit advantag bgne global player term access chines market
current size commerci access oncolog market china rel us
give confid zanubrutinib uniqu properti pk profil result differenti clinic profil compar btk inhibitor
registr strategi zanubrutinib cll
retain asian right ex-japan tislelizumab inhibitor partner celgen help us understand agent posit china rel
updat zanubrutinib btk inhibitor phase monotherapi combin data
updat tislelizumab phase monotherapi combin data
present tislelizumab china pivot trial data
present updat pamiparib parp inhibitor phase monotherapi combin data
hurdl success file monomethyl fumar mmf multipl sclerosi ms differenti expect toler
spinraza spinal muscular atrophi sma adopt around world mostli confin type sma treatment persist observ us older
tysabri acut stroke result immin success look like confid mechan action indic
aducanumab alzheim diseas
recruit proceed pivot trial convers rate patient refer screen confirm elig random
research landscap evolv alzheim still faith amyloid hypothesi alzheim diseas
look ahead potenti commerci aducanumab durat exposur would expect real world would right trigger start
discontinu treatment plan studi combin aducanumab
recent flag ophthalmolog neuropsychiatri new area futur invest compani program area today type
indic interest area
tysabri phase iib dose rang trial result acut ischem stroke
raxatrigin phase iib trial result lumbosacr radiculopathi
nda file us multipl sclerosi
phase ii trial result alzheim diseas
short interest float
outstand quarter saw one best quarter recent histori organ remark us bit quarter market wise
biggest driver much contribut think year-end budget flush end-market wise scientif applic wise think drove strength
acd acd expect platform year today impli higher growth talk could walk us thru
area growth biopharma diagnost think get expect mix biopharma diagnost
deliv growth last quarter help us understand shouldnt see go forward
assay market growth what driver growth immunoassay market think take share larg market growth see
 could pleas elabor us area interest go forward perspect
acd posit grow y/i near-term deeper penetr diagnost
market new partnership could drive even growth
protein platform grow y/i could higher placement simpleplex instrument
increas per quarter
primegen headwind china resolv china drive growth
short interest float
recent provid guidanc timelin regulatori file beta thalassemia patient europ remind us gate factor file
data go document
sickl cell diseas scd comfort safeti profil apheresis-bas cell collect method result inform
possibl design pivot studi scd
recent complet dose-escal studi celgen initi pivot line phase ii studi plan start randomized-control trial line
patient year interim efficaci analysi plan karmma trial
lentiglobin tdt data data
mm data
lentiglobin scd data
mm data
lenti-d cald starbeam data
short interest float
analyst daniel antalffi medic suppli devic
outlook ep growth guidanc seem recent year aspir sustain double-digit ep growth long-term talk
whether still aspir chang specif impact could push ep growth double-digit
posit oper leverag posit oper leverag less dramat peopl hope path toward oper margin
potenti upsid driver
balanc sheet exit significantli better posit balanc sheet/cash flow perspect call cash gener
beyond ir transfer price mesh litig settl bsx capit deploy prioriti balanc sheet freed
long-term sale growth outlook base bsx combin busi mid-to-high singl digit long-term growth outlook reason consid end-us market
growth bsx posit within market
underappreciated/overappreci asset area think street underappreci street over-focus
lotu lotu edg eu re-launch launch expect
acur trial plan
scope trial enrol on-go result expect
scope ii trial enrol on-go result expect
watchman patient unsuit oral anticoagul asap-too trial enrol
patient fda approv expect
watchman japan watchman japan launch expect
watchman flx ce mark trial begin ce mark expect late
 trial begin launch expect earli
eluvia drug-elut vascular stent imperi trial data expect fda approv
short interest float
expect
vercis deep brain stimul pc gevia launch
acceler trial result expect
analyst seamu fernandez
elabor discuss fda regard analysi file expect opdivo nivolumab yervoy
ipilimumab first-lin non-smal cell lung cancer nsclc use tumor mutat burden tmb success approach file
approv would compar
see tmb replac supplement use express biomark treatment decis nsclc benefit look tmb nsclc
uniqu monotherapi combin yervoy believ help identifi patient like respond immunotherapy-bas regimen
investor expect learn present result use tmb analysi
plan incorpor tmb biomark opdivo /- yervoy tumor type indic believ would benefit ad
replac test tmb test next month like learn tmb particularli use either refractori patient perhap
earlier stage cancer
see opdivo yervoy posit renal cell carcinoma rcc rel rhhbi nr tecentriq atezolizumab avastin bevacizumab anti-
vegf antibodi upcom data variou vegf tki combin
larg opportun io adjuv treatment earli stage cancer across tumor type under-valued opportun io overal today
view
emerg io target see excit whether intern outsid might learn view opdivo pegylated-
pdufa date opdivo dose across tumor type march
pdufa date opdivo yervoy renal cell carcinoma rcc april
data opdivo small cell lung cancer sclc
data opdivo /- yervoy sclc mainten
data opdivo hepatocellular carcinoma
final os data portion late
short interest float
attende frank laukien presid ceo miroslava minkova head ir
portfolio transform big focu sinc last year still on-going high growth high margin portfolio help deliv beat vs street
expect area among portfolio initi room deliv near immedi term among product line proteom
biopharma microbio neurosci next-gen nano after-market servic
portfolio part portfolio transform initi excit longer term
europ what sustain growth europ think eu academ market updat us order outlook well
market outlook eu region overal
ultrahighfield magnet didnt get one last year expect one year chanc could expect one higher
sustain oper margin initi could elabor sustain oper margin initi think improv longer-
term lever pull improv profil could pleas elabor intern effort
larg portfolio initi improv growth drive margin
sale could significantli increas nmr revenu revenu signific
per order system cost
reorgan initi dalton restructur could expand oper
sap system improv could help drive oper improv
short interest float
view evolv renal cell carcinoma rcc landscap see potenti posit landscap
talk rational shift focu rcc toward cabozantinib combin opportun away everolimu combin
compar drug develop tripl neg breast cancer tnbc could path forward tnbc look like
arginas inhibitor compar inci epacadostat inhibitor
investor expect updat ongoing/plan studi
plu paclitaxel phase ii tnbc data
plu opdivo phase i/ii updat
short interest float
highlight differ kappa-agonist vs opioid receptor target make better posit vs past drug class
would expect includ bundl payment chronic kidney diseas ckd patient dialysi
studi post-op pain chronic pain think priorit two program
post-op pain data present phase studi surgeri type assess phase studi
latest thought develop plan intern
oral ckd-associ pruritu phase studi initi
short interest float
plan save tax reform expect reinvest busi capit return sharehold
competit state sell-sid year area concern
view amazon entri medical/surg suppli distribut latest hear hospit client shift
procur amazon
narrow/pref network continu prolifer pharmaci market mean price pressur distributor cah mix revenu retail
pharmaci provid
earn expect med-surg busi challeng work
newli acquir patient recoveri busi track margin compar core exist medic segment
cost/buy side price drug seem slightli better expect red oak perform peak increment discount extract
talk necessari re-invest back busi especi side
drug price commentari washington
sell-sid confer appear commentari drug price
news flow around amzn foray medical/pharmaceut distribut and/or retail
core busi seem improv base result
short interest float
give us updat price approv effort xydalba improv uk franc germani last six month new countri
expect approv
zevtera complement strateg plan xydalba pleas highlight develop mileston expect
could outlin deliveri advantag trevyent would provid patient parallel infer eu submiss trevyent light fda feedback
steadym receiv us submiss
latest thought potenti us regulatori pathway brinavess
much capac expect within commerci organ type product look bring onto portfolio
initi brinavess phase trial recent onset af china potenti earli
launch zevtera/mabelio spain ireland
launch xydalba belgium netherland
eu file trevyent late
short interest float
analyst daniel antalffi medic suppli devic
outlook gotten increment wors late octob today prompt move downward guidanc particularli given actual
come low end guidanc rang confid updat guidanc achiev
long-term outlook assess peripher knee coronari busi end user market perspect long-
term growth trajectori specif
new role is/wil recently-announc rhonda robb key prioriti first month compani see possibl area
competit landscap notabl chang occur competit landscap last month product cycle/pricing/bundl perspect
particularli see obl office-bas lab weak recent quarter
profit quickli compani reach sustain profit particularli given ramp expens tie eclips grow salesforc
japan launch japan second largest coronari market product launch expect
eclips trial eclips prospect multi-cent random clinic trial approxim
subject sever calcifi coronari lesion unit state februari
patient site enrol result expect
liberti studi data expect
short interest float
celgen revenu growth never less sinc revlimid launch confid manag record maintain
revlimid loss exclus
celgen recent announc settlement abraxan expect addit settlement revlimid might bring gener entri sooner
oper margin trend recent acquisit cost launch ozanimod luspatercept loom
partner product luspatercept car-t result lower gross margin long term expect oper margin recov even cost make
launch car-t program get back oper margin achiev
celgen alreadi made two acquisit hematology/oncolog area focu compani busi develop effort
expect revers compani typic partnership model
much increment capit plan invest share repurchas inclin take advantag current share price weak
revlimid augment trial result r/r follicular lymphoma
revlimid robust trial result newly-diagnos activ b-cell diffus larg b-cell lymphoma
otezla relief phase trial result behcet diseas
luspatercept phase trial result md beta-thalassemia
quazar phase trial result mainten acut myeloid leukemia aml
short interest float
area allogen shelf therapi could differenti autolog program influenc pipelin strategi
opportun posit treatment landscap vs autolog product
septemb phase studi place clinic hold lift novemb revis phase protocol
walk happen implic pipelin platform
talk posit car-relaps space develop strategi rel
bcma compar car-t target multipl myeloma
phase interim updat
phase interim updat
ind
short interest float
discoveri custom could elabor strength discoveri demand market
safeti us bit appetit safeti busi alreadi success complet eight acquisit
small biotech compar last year growth level see small mid-siz biopharma biotech
margin could lay part busi see strong margin improv opportun still
asia what sustain growth china benefit research model
short interest float
select palovaroten treatment term reduc patholog bone format vs healthi bone growth fibrodysplasia ossifican progressiva fop popul
discuss key find optim implement move trial design
expect see term safeti efficaci part trial evalu chronic regimen palovaroten adult month exposur
interpret efficaci data trial given sub-optimal statist power
regard ph trial evalu palovaroten multipl osteochondroma mo evid exist support palovaroten meet studi primari endpoint
discuss highlight dri eye syndrom de program palovaroten de development well regulatori timelin
surround program
preliminari result on-going part chronic regimen adult month
initi link cmta lead program track link
short interest float
comput program system inc market perform
market competit went road togeth septemb describ back hospit athn earn call
describ market competit hell disclos close new deal would character level competit success
compet
product develop earn call sound though busi develop dashboard gener interest user base expect
increas ahead develop target toward emerg room chronic care manag provid growth track product
develop addit solut progress
book would describ book pipelin gener mood potenti custom go bid
capit deploy octob complet amend credit agreement describ move provid flexibl capit deploy
 invest acquisit opportun identifi led amend think acquisit would describ capit
deal financ percentag deal done long-term arrang saa financ perpetu licens mean revenu
describ opportun rural effort initi success/challeng posit value-bas care popul health product offer
short interest float
face challeng revenu beat impress seem resili demand seem stabl
attende curt hartman presid ceo todd garner evp cfo
sherri bertner founder bertner advisor llc kevin ciabattoni lead client
advisor bertner advisor llc
behind posit spike us ortho growth rate come prior consecut qtr growth sustain level growth
go forward kind us ortho growth perform rang contempl management cc overal revenu growth guidanc mani kind
new product expect see launch ortho divis
primari driver higher gross margin increas oper leverag increment tailwind headwind consid behind
management outlook y/i gm improv estim guidanc impli adj ebita margin y/i would potenti sourc
upsid figur downsid long-term goal post op margin could go next year
extent pull-through cross sell airseal begun materi legaci gener surgeri product portfolio driver growth recent
quarter big overal airseal ww market opportun robot non-robot penetr airseal potenti robot opportun penetr airseal
potenti laparoscop non-robot opportun effort focus within gen surgeri come month biggest product
management strategi size deal small tuck-in vs larger deal expect move forward busi unit near-term prioriti
new gener surgeri launch sage apr
new orthoped launch -- aao
short interest float
seen phase program system sclerosi inform use guid phase
size market opportun lenabasum system sclerosi
pleas describ phase cf studi design expect compet patient
market opportun lenabasum cf bring tripl market
goal upcom type meet fda dermatomyos
initi patient dose trial system sclerosi
initi patient dose program sle
initi patient dose program cf
short interest float
corbu success discuss cf studi design fda link corbu aim treat rare inflammatori fibrot diseas link
donepezil complet pilot bioequival trial last year abl show statist updat fda whether
serv pivot
corium decid progress pivot studi donepezil anyway give us overview studi design differ pilot studi
mileston timelin
next candid corplex technolog youv highlight memantin what latest program mayb could give overview
development project area target well might see corium move toward get
twirla partner fda issu decemb highlight number concern includ observ identifi
corium facil give us updat thing stand dialogu fda address issu affect development/product
product portfolio youv announc plan add manufactur capac crest whitestrip extend suppli agreement
current capabl much addit capac expand stage expans corium current
new phase program expand franchis
short interest float
attende alessandro della ch ceo john manieri head ir
eleview launch mani state licens also provid updat order variou hospit
methylen differ gener market today think commerci strategi market potenti product
give confid rifamycin sv could effect current treatment address ibs-d
recap us result complet registr trial remimazolam pre-nda meet fda yet
sale forc capac current think sale forc expans multipl new product launch expect next two year
pdufa methylen may
rifamycin sv ibs-d trial complet
nda file remimazolam
short interest float
data gener seladelpar primari biliari cholang pbc thu far meaning alkalin phosphatas ap reduct effect
interim updat amend protocol expand current cohort mg also add mg arm hope demonstr final
previous guid data updat pbc investor expect
final pbc trial protocol regul need happen initi studi
intend initi anoth studi nonalcohol steatohepat nash preclin evid support decis
data seladelpar primari biliari cholang pbc
initi studi seladelpar nonalcohol steatohepat nash
data seladelpar pbc
initi studi seladelpar pbc
data seladelpar pbc
short interest float
kol event suggest seladelpar could attract treatment option pbc link pbc survey link
respond rate cumul reactiv dose crd seen phase pepit trial
primari endpoint phase specif fda want see
think fda encourag continu bla file process preced allergi medic
sinc pepit trial enrol age plan address younger pediatr patient
program leverag epicutan immunotherapi epit platform
short interest float
talk strategi cosyntropin indic pursu clinic requir indic timelin key develop
youv talk build new specialti busi help us think type asset therapeut area interest
nucynta arrang collegium close last month depom strategi go forward pain space
neurolog area depom highlight product gralis cambia effort put around asset drive growth
think depom strategi therapeut area
think restructur effort underway debt paydown potenti busi develop
ind trial cosyntropin infantil spasm
pre-trial confer set trial date purdu litig
execut busi develop opportun
nda file cosyntropin indic late
short interest float
analyst seamu fernandez
acn import result agent deliv view best-cas result might differenti minimum regulatori
threshold approv
discuss clinic team done minim risk failur phase studi identifi develop limit recent acn program
failur give confid program minimum avoid issu true test drug efficaci safeti
pleas discuss market opportun unmet need axillari hyperhidrosi commerci expect topic wipe accept vs
discuss lebrikizumab oppti includ chanc differenti competitor atop dermat pediatr popul area lebrikizumab could
play uniqu role assum smooth develop program phase lebrikizumab kind label mi ght abl launch product
decis financ lebrikizumab deal mani investor strong indic confid like success program meet expect
fulli fund success complet phase develop lebrikizumab also fulli fund launch
strateg derm evolv becom commerci organ opportun see busi beyond three main product believ kind
consolid weve seen dermatolog last decad like continu year ahead
top-lin read-out two phase trial
initi phase dose-rang studi evalu lebrikizumab patient moder
sever atop dermat
fda regulatori decis pdufa date
launch assum approv
short interest float
talk mechan dcr-phxc differ mean applic regard across primari hyperoxaluria ph genotyp
sever versu would clinic develop approach trial design and/or regulatori path differ across genet subtyp
think competit dynam market might sanofi op opt-in decis alni mp lumasiran influenc think
respect efficaci think would requir garner fda/ema approv
what statu on-going litig what expect outcom
short interest float
addit research conduct market prophylact treatment thrombocytopenia chronic liver diseas cld indic
size cost commerci build-out requir support launch us thrombocytopenia cld much larger commerci
requir idiopath thrombocytopen purpura itp
avatrombopag profil compar shinogi competitor lusutrombopag thrombocytopenia cld current expect time competit
time outlook develop avatrombopag itp chronic dose chemotherapy-induc thrombocytopenia
expect dose price compar thrombocytopenia cld short cours
prefer financi structur time avatrombopag eu partnership
avatrombopag pdufa thrombocytopenia cld patient
avatrombopag european ema submiss potenti commerci partnership
avatrombopag snda immun thrombocytopen purpura itp
short interest float
attende brian leuthner ceo andrew saik cfo greg gin head ir
design perspect phase studi compar design phase ii
power statist hurdl trial compar hurdl clinic meaning effect
recent futil analysi rule futur futil analys interim
degre clinic endpoint intertwin abil demonstr pharmacoeconom valu
think potenti price rel standard care degre capac premium price vari base effect size
show phase
short interest float
compani market perform
analyst seamu fernandez
partner anti-ngf antibodi tanezumab phase across number pain indic data read start year talk us size
opportun tanezumab lot work went ph design mitig risk around program particularli rpoa rapid progress osteoarthr rpoa
think anti-ngf mechan level comfort around benefit-risk tanezumab
ph top line novo oral program expect quarter speak oral clinic develop plan program
differenti oral semaglutid
key takeaway solanezumab alzheim diseas ad studi take-away shape futur ad drug develop
number cardiovascular trial read year trulic rewind tradjenta carolina carmelina lot made studi
popul youv select rewind trial given import space speak tradjenta data could impact space
talk indic opportun verzenio updat could get program
rewind studi result trulic dulaglutid agonist
strateg decis anim health
phase data readout tanezumab nerv growth factor osteoarthr pain
galcanezumab anti-cgrp antibodi migrain pdufa
baricitinib jaki rheumatoid arthriti pdufa
detail data phase trial alimta pemtrex platinum chemotherapi
mrk mp keytruda pembrolizumab first-lin non-smal cell lung cancer nsclc
short interest float
mavyret royalti royalti mileston durat
fxr agonist pbc nash nafld profil compar oca competitor optim trial design patient definit trial recruit
issu resolv follow nash compound class develop plan
rsv antivir profil potenti dose schedul
hbv progress toward real cur treatment core inhibitor capabl elimin hbsag
phase ii trial result pbc nash
rsv first human efficaci data
hbv clinic candid select
short interest float
type account compani challeng win back relationship and/or reviv afx util follow reintroduct jan
afx busi stabil posit elgx aggress go offens
ovat sustain dd growth busi advantag ovat afx advantag enough retain prior afx account push ovat
util expens afx ovat alto still track pma submiss approv
nellix intenational growth rate stabil begin build momentum cours nellix eva mortal dataset produc independ research firm still
present apr nellix cheva approv timelin eu still line us approv
management view overal us ww market growth rate elgx posit grow in-lin market rate management view share gain potenti
next year
swing factor put compani toward upper end revenue guid low- mid-single-digit revenue growth profil realist goal post
compani plan balanc spend vs drive top-lin growth
earn call schedul wednesday februari
clinic present
elev trial ovat alto enrol complet expect
leopard trial updat dataset expect
encor trial ovat aggreg analysi expect scv
nellix eva mortal data present expect apr
luci trial ovat follow-up result expect jun sv
ovat alto pma submiss approv expect
us product approv nellix nellix cheva
short interest float
elgx earn call schedul pm
might epizym expect first approv commerci meaning indic popul
solid tumor show promis respons tazemetostat larg patient popul
expect epithelioid sarcoma commerci meaning indic
updat investor regulatori strategi tazemetostat nhl ezh follicular lymphoma fl clinic trial recruit progress
final pivot develop plan tazemetostat dlbcl promis popul combin
progress made cellular therapi relapsed/refractori set dlbcl potenti chang tazemetostat posit
could updat us statu find new
updat phase i/ii data follicular lymphoma dlbcl
phase ii data present tazemetostat mesothelioma
dose escal data lysa phase ib/ii studi dlbcl
nda file tazemetostat epithelioid sarcoma
recent note what come tazemetostat
short interest float
complet test test came line street despit strong doc add could elabor bit acceler lack quarter
street expect appear reachabl base comment earli januari think context prior conserv
blood base screen test seen nois late blood base potenti competit test help us understand screen blood base marker
challeng perhap elabor advantag dna methyl method vs liquid biopsi context screen
rais given recent two capit rais expect time profit
pipelin pipelin test excit get see data updat
shift electron order system away paper fax order increas
penetr rate cologuard
recent ad sale rep could drive deeper growth penetr
pcp
test pipelin includ liquid biopsi lung cancer pancreat cancer blood-
base test could provid anoth growth driver
short interest float
two year cabometyx launch rcc volum growth come right
import front-lin rcc label support volum growth sinc approv decemb
see cabometyx compet also market undergo rapid chang inhibitor tki enter market
lot excit around trial read soon talk takeaway recent phase ib updat asco-gi
confid ip runway cabometyx
cabozantinib hepatocellular carcinoma line snda file expect
cabozantinib line rcc cabosun subgroup analysi updat asco-gu
cobimetinib plu atezolizumab colorect cancer ph data
short interest float
scaffold structur differenti linear rnai antisens drug
anti-tnf program look phase advanc measur knockdown tnf level
knockdown look
anti-tnf compar antibodi leverag similar mechan
would phase studi look like term number patient endpoint
think partnership respect variou therapeut modal skin immuno-onc etc
short interest float
nk cell compar cell potenti therapeut
compar nk cell approach pursu
indic higher likelihood success base preclin work past nk-cell therapi studi
advantag challeng creat off-the-shelf product use ipsc approach differenti approach hope creat off-the-
protmun differenti approach aim address gvhd
r/r aml voyag platinum-resist ovarian cancer apollo phase data
initi phase dimens studi
ind file
ind file
short interest float
compel cabiralizumab plu opdivo pancreat cancer data context activ alon agent set
could investor see cabiralizumab data tumor-specif cohort phase ib studi
learn inhibitor develop
size address commerci opportun pvn path market
regard registr studi front-lin gastric cancer biomarker-select patient level efficaci would one expect folfox patient alon
mab gastric cancer ref ph updat
cabiralizumab phase updat
short interest float
recent european patent offic revok patent opposit proceed could comment reason timelin potenti appeal
us last year uspto found claim patent argument present far appeal process
key event investor expect us eu appeal year think time ultim reach final decis
key pushes/pul see influenc futur tecfidera sale
eu appeal expect written decis argument
eu appeal forward pharma file appeal technic board appeal
eu appeal final outcom appeal
short interest float
mechan action aramchol nonalcohol steatohepat nash liver diseas
hope see arriv studi could impli arrest studi
much effect hope see fibrosi vs na score arrest studi
approach attempt address nash nonalcohol fatti liver diseas nafld increas glutathion concentr
approach compar
thought mri-deriv proton densiti fat fraction imag mri-pdff mean evalu abil improve/resolv nash
top-line arriv data readout aramchol hiv-associ
lipodystrophi nafld
top-line arrest data readout aramchol nash
short interest float
focus develop commerci aramchol first-in-class famili synthet fatty-acid/bile-acid conjug fabac
elafibranor compar peroxisom proliferator-activ receptor ppar agonist
main challeng enrol nonalcohol steatohepat nash supposedli vast market opportun
remind us saw golden studi execut order avoid pitfal encount
hope see term nash resolut vs fibrosi also primari endpoint statist analysi plan compar
use
pharmacoeconom data use put clinic benefit hope demonstr context payor
end enrol elafibranor adult nash
data readout elafibranor pbc
posit outcom resolve-it trial evalu elafibranor nash studi continu without modif link
voxelotor sickl cell diseas
impact breakthrough fast track design develop plan interact regul
number patient phase trial enrol on-going open label extens patient ole
patient hemoglobin hb respons clinic benefit seen phase cohort
durabl stabil hb respons
clinic impact requir use voxelotor addit hydroxyurea proport scd patient hu today
studi start enrol data dose studi announc full efficaci result voxelotor arm
year compromis on-going part
voxelotor previous develop idiopath pulmonari fibrosi ipf still forese indic
part top-lin result pivot trial
top-lin result dose
top-lin result studi
short interest float
key assumpt underli management above-consensu y/i revenue growth outlook specif pertain us core spine growth rate growth
 robot revenue contribut trauma contribut much anticip windfal stem lower tax rate tax reform like reinvest vs drop
bottom line beyond alreadi ear-mark increment spend trauma robot even reinvest safe assum like still manag
gener ebitda margin management reinvest prioriti emerg trauma robot vs sale forc hire
rate management believ us spine market grew rate growth us spine market management assum revenue growth outlook
would management character price pressur spine stabl improv worsen compar last quarter management estim like-for-lik price excl mix
benefit management hear sign increas insur pushback us spine procedur
base preliminari result estim excelsiusgp robot place oct dec quarter ahead consensu expect -- -how much
better-than-expect robot revenue due pent demand vs sustain go-forward demand placement oper leas vs outright capit sale
mani capit sale rep current target much increment tailwind could robot placement implant sale will
engag custom robot system rebates/discount exchang minimum implant volum commit think robot initi
phase launch well longer term expect see data public robot
compani remain track launch addit new trauma product routin trauma case initi product suite/portfolio capabl
address management think minimum threshold necessari give new entrant foot-in the-door major trauma practic
think revenu cadenc throughout gradual sequenti growth might see inflect year trauma realist sale rep
hire go expect full trauma sale forc place target scale
anticip fda approv trauma earli
expand indic excelsiusgp
earn call schedul pm
short interest float
view what biggest outstand risk epidiolex approv
investor think move part around pdufa schedul expect epidiolex codif long
process take
regard epidiolex adcom speak on-going prepar see overarch themes/quest fda may interrog
kind resourc expect need launch epidiolex mani rep well fund gw launch drug independ around world
gw said statist signific hurdl cbdv cannabidivarin advanc expound upon sort magnitud clinic effect
seizur reduct would serv good outcom
preclin talk strength evid cdbv anti-epilept preclin profil compar cbd cannabidiol
short interest float
addit color around volum strength driver guidanc believ gain market share not-for-profit competitor
volum track impact intens flu season
hca outpati strategi off-set volum pressur across ambulatori free stand emerg depart ed urgent care
capit deploy opportun post tax reform across capital-expenditure share buy-back recent uptick
earn impact intens flu season
updat measur build altern site care off-set payor pressur shift
outpati
addit updat newli announc dividend deploy tax reform proce
top facil pick review avail follow link
short interest float
pivot phase studi like read soon give us summari paramet studi done data weve previous seen
highlight phase studi breast augment total knee arthroplasti data seen previous indic would market opportun
expand posit data
latest think potenti partnership opportun
give us updat cinvanti launch go
expect sustol updat gener aloxi could come market
top-lin pivot phase result bunionectomi herniorrhaphi
phase result total knee arthroplasti breast augment
sale ramp cinvanti
link heron initi report link
short interest float
factor give management confid medic aesthet segment cyno pois see posit momentum throughout cyno sale forc fulli train
exit management estim aesthet end-market growth rate
tempsur dispos revenu price point signific new product cycl platform address market size revenu gener
capabl compar cyno success launch past year sculpsur picosur mona lisa touch
factor could drive revenu upper end lsd rang breast health divis
cc revenue growth sustain intenational breast health busi move key engin growth diagnost busi
long take return surgic gyn segment back growth key area invest like need achiev management expect tuck-in
one possibl invest area potenti product gap surgic portfolio could benefit potenti tuck-in
reinvest tax reform relat benefit like keep op margin expans y/i somewhat limit think long-term gross oper margin
expans potenti busi annual improv beyond reason
addit tempsur indic surgic women health expect
addit sculpsur indic back thigh expect
novasur advanc myosur manual approv us
short interest float
attende tj johnson ceo shaun mcmean cfo svp financ
strong quarter pre-announc strong quarter help us understand drove quarter acceler saw
collabor revenu collabor appear deliv growth think continu momentum program near term
technolog make uniqu leverag exist box market compani number agreement primari
sequenc compani pleas explain implic htgm
pharma htg announc number companion diagnost agreement larg biopharma investor look agreem ent near term longer
liquid biopsi emerg area number compani think space potenti opportun pursu
agreement mileston
grow number pharma partnership
short interest float
havent therapeut cancer vaccin work past key lesson learn imdz differ give confid approach
investor expect next updat phase ii plu atezolizumab combin studi
reason confid head phase ii plu atezolizumab combin updat investor think matur surviv
reason confid plan phase monotherapi frontlin mainten studi synovi sarcoma
think next develop step follicular lymphoma potenti indic
updat phase ii plu atezolizumab st data esmo earli
regulatori feedback determin clinic path forward
short interest float
mirvetuximab on-going singl agent phase trial platinum-resist ovarian cancer futil analysi expect soon go/no-go criteria
regard mirvetuximab plu avastin combin studi would consid win term efficaci
keytruda littl activ ovarian cancer alon lot activ combin inhibitor parp inhibitor level activ top mirvetuximab
would consid suffici advanc combin
fall last year announc partnership regard two asset aml set potenti advantag new payload
technolog use agent
well-known target aml speak potenti develop path mylotarg approv front-lin set
mirvetuximab single-ag ovarian cancer forward-i ph interim futil analysi
mirvetuximab combo keytruda ovarian cancer forward ii ph ii dose-escal
expans data like sgo/esmo
mirvetuximab combo avastin ovarian cancer forward ii ph ii dose-expans data
like
dna-act ign aml ph updat data
dna-act ign aml ph initi data
short interest float
inhibit elus target drug develop discov import select inhibit concomit
preserv activ
briefli describ hidraden suppurativa hs current standard care differenti
previou trial evalu hs patient anti-drug antibodi detect one particip expand presenc anti-drug bodi
presenc affect efficaci
also studi data indic patient respons rate continu increas day discontinu therapi despit recoveri serum level
restor neutrophil activ insight explain phenomenon
describ role anti-neutrophil cytoplasm antibodi anca associ vascul aav data support use aav
statu ip either diseas
complet enrol trial evalu hs
top-line data trial hs
initi link ind clearanc fda start ph iib trial link
short interest float
attende scott wilkinson presid ceo ali bauerlein evp cfo
analyst daniel antalffi medic suppli devic
long-term growth base recent medicar data portabl oxygen concentr poc ad anoth point penetr vs ad point
penetr per year sustain ultim right way think long-term busi mix direct sale rental keep
surpass direct sale growth size consid home medic equip hme control major patient
outlook put take guidanc could drive faster slower sale growth manag biggest potenti sourc posit upsid
surpris convers biggest potenti risk signific sourc upsid last sever quarter still increment runway
upsid sale
posit oper leverag steadili ad new sale rep drive growth compani gener increment posit leverag on-going basi
key area invest opex perspect ramp invest sell market put pressur near-term oper margin
manag view reason long-term oper margin goal busi
competit landscap manufactur alreadi well-entrench relationship hme recent announc first poc product launch see
competit landscap evolv next month
strateg initi cash hand debt financi flexibl diversifi acquisit hat compani strateg prioriti
one product launch on-go
short interest float
vice-president head ir laura perri ir
recap convert data evalu amikacin liposom inhal suspens ali nontubercul mycobacteri ntm caus mycobacterium avium
complex base recent data anticip ali prescrib long-term mainten use
still track file nda end march could provid guidanc price anticip sale assum approv
commerci plan ali japan consid larger market opportun plan pursu partnership timelin
plan ali front-lin mainten therapi non-mac ntm speci
what beyond ali updat willow studi non-cf bronchiectasi non-cf pulmonari arteri hypertens pah
march nda submiss ali
may addit data american thorac societi at meet
late japanes nda file japan ali
potenti blind interim look willow studi non-cf
short interest float
posit data ali derisk program prepar nda file link focus key growth driver ali link
remind us saw preclin rodent model mice rat transthyretin amyloidosi ttr singl administr grna
ind-en studi undertak ind file possibl
step taken limit off-target effect grna investor concern recent public cite off-target effect
kite juno acquisit rais investor interest car-t nv partnership investor hear next updat
corpor deck show central nervou system cerebellum striatum next target organ natur progress
indic work
short interest float
uptak ocaliva primari biliari cholang pbc chang sinc dear hcp fda warn letter emerg last year
fda recent updat ocaliva label pbc briefli comment amend
enrol progress regener studi nonalcohol steatohepat nash see notic impact competitor emerg
ocaliva develop pbc letter label updat affect patient enrol regener
plan initi revers studi cirrhot nash patient
initi revers cirrhosi studi nonalcohol steatohepat nash
potenti strategi updat primari scleros cholang psc
interim regener data nash patient
short interest float
management break sinuva market opportun estim patient much could repeat use sinuva expand sinuva
potenti market opportun alreadi includ management estim
type sale forc doc train initi compani implement ensur success sinuva launch posit initi user experi
compani market access program go live separ educ effort physician learn product acquisit buy bill vs specialti pharmaci
reimburs interim
compani prepar mitig potenti reimburs risk use unassign j-code type physician administ drug launch management
analyzed/studi give increas confid unassign j-code submiss process specialti pharma success reimburs
compani remain track submit perman sinuva j-code jan approv perman j-code differ unassign j-code
term likelihood speed eas reimburs process
long management expect initi contour ineffici drag gross margin introduct sinuva present similar type sub-scal
product gm headwind initi factor give management confid sustain futur reason sustain oper profit
would delay beyond late even assum invest relat sinuva physician training/support
give management confid base busi propel propel contour continu grow or/ surgeri set compani expect see
contour adopt offic set
sinuva commerci
j-code expect
short interest float
earn call schedul pm
speak fda feedback regard lumateperon data set gave confid file nda start addit trial schizophrenia
hedg appropri path
matter one posit efficaci studi lumateperon phase ii
think mechanist rational lumateperon bipolar versu schizophrenia speak rel import serotonerg dopaminerg
modul context els import
atyp antipsychot abilifi succeed schizophrenia fail bipolar depress exampl past failur learn
bipolar depress
degre believ upcom data lumateperon bipolar disord may read schizophrenia review could matter approv
lumateperon nda file schizophrenia
short interest float
attende sean georg ceo shelli guyer cfo kate mcneil head
test volum recent appear focu guid shift volum help us understand what drive asp uncertainti expect
model expect go forward term metric busi
commerci contract much guid volum would say lock year commerci contract mention earlier think
asp go forward hereditari reproduct part portfolio
market growth competit see market growth current hereditari test reproduct test compar expect
competit space last year
nipt nipt continu area still lack reproduct test portfolio thought could potenti see test
cog expect reach gross margin much come increas volum mayb outlin us initi look
drive reduct cog especi among newli acquir busi
start genet combimatrix acquisit still integr resolut integr
process could lead better visibl increas volum
code still uncertain pama price clearer understand around gene
panel sequenc reimburs rate could lead increas revenu
util novaseq instrument nvta lab could lead lower cost
exom test oncolog gain adopt outsid genet counselor commerci
short interest float
attende philip sawyer ceo jim macka cfo
key assumpt photonblad core dispos busi underli revenue outlook key driver would put
low-end excess revenu guidanc think quarterli cadenc photonblad
given photonblad first full quarter launch realist think product revenu management
anticip photonblad cannib distract sale forc attent sell legaci product portfolio step compani take
address and/or minim situat
earli feedback adapt waveguid gyn gener surgeri case compani initi target estim
market oppti
long rep hire follow attrit take becom fulli product
compani feel cash posit compani anticip need rais money near-to-intermedi term
factor behind get back gm profil possibl
photonvu full-scal launch expect
adapt waveguid initi commerci earli
short interest float
analyst daniel antalffi medic suppli devic
outlook strong near mid-single-digit growth organ drive slow momentum organ sale growth guid
headwind tailwind consid specif across busi growth outlook across busi specif within consum medic
devic saw below-market growth
posit leverage/ep growth area posit leverag busi increment opportun jnj ep
guidanc reflect high-single-digit ep growth ever compani grow ep double-digit get
capit deploy tax reform what latest priorit potenti capit deploy aggress commentari call regard
post-tax reform environ see glare white spaces/excit new market think realiz leverag
portfolio optimization/invest guidanc seem assum on-going portfolio prune criteria determin whether divest shut
asset reinvest increment proce top area invest busi
medic devic seem rel strong devic across board earli sign see hospit admiss procedur volum growth
sustain think
short interest float
conduct storm singl agent singl arm phase ii/iii trial penta-refractori patient gain acceler approv view address market
compani on-going phase boston studi line mm patient current enrol statu expect data readout
sadal studi evalu selinexor diffus larg b-cell lymphoma dlbcl confid uncontrol studi could registr dlbcl
recent approv car-t dlbcl forese posit selinexor drug get approv later line address patient popul
selinexor vs car-t
develop plan next-gen nuclear expert inhibitor agent differenti selinexor
selinexor storm ph ii top-lin data r/r mm penta-refractori april
selinexor liposarcoma ph ii seal full data medic meet undisclos
selinexor sadal ph iib top-lin data dlbcl r/r line
short interest float
tipifarnib studi patient across multipl trial past broad effort across hematolog solid tumor talk what shown
past key lesson learn see opportun
see squamou cell carcinoma head neck scchn landscap evolv see tipifarnib posit head neck cancer treatment
youv previous disclos patient recruit challeng head neck cancer landscap talk challeng step youv taken address
challeng progress youv seen front
youv guid initi registration-en studi hrasm scchn talk registration-en studi could look like term studi size
design
reason confid tipifarnib squamou cell cancer hematolog malign
updat phase ii hrasm scchn tipifarnib data multidisciplinari head neck cancer
phase ii data myelodysplast syndrom md peripher cell lymphoma
chronic myelomonocyt leukemia cmml like
initi registration-en studi hrasm scchn
preclin biomark data potenti phase data
short interest float
light recent fda experi sponsor testosteron replac therapi trt give confid fda would approv anoth trt
pleas comment cash posit light product pipelin potenti regulatori work requir address concern fda may tlando
recent advisori committe meet rais concern off-label use trt product lipocin plan address concern especi around
initi tlando ambulatori blood pressur studi
lpcn fda pre-ph meet overal ph develop plan
lpcn continu explor out-licens opportun
short interest float
instal base provid detail current instal base plan address platform may greater sensit capabl
verigen could provid updat verigen think timelin launch whether plan push thing back
season expect season assay busi seen benefit budget flush
 could elabor us area interest term potenti tuck-in expand portfolio
nanospher could updat us nanospher gross margin expect longer term
short interest float
interim futil analysi on-going phase sophia studi margetuximab breast cancer pass give confid success chanc trial
efficaci assumpt control treatment arm
regard recent phase ii data margetuximab combin keytruda reason discrep data gastric gastroesophag junction
sever agent target statu on-going clinic studi investor expect data studi
bispecif antibodi platform compar other space
defin futur develop plan franchis includ enoblituzumab base
monotherapi combin studi result
updat margetuximab phase gastric cancer data
short interest float
walk us histori ganaxolon develop product initi own marinu
ganaxolon examin hand indic epilepsi fragil ptsd hasnt yet found nich specif patient popul majorli
differenti think
talk pharmacokinet pk properti ganaxolon drug gone multipl formul iter comfort current
form well posit success
talk design on-going post partum depress trial constitut success
studi examin iv formul ganaxolon properti iv compar oral formul
ganaxolon initi clinic studi defici disord
ganaxolon phase ii data magnolia studi earli
ganaxolon phase ii data amarylli studi
ganaxolon phase ii data super refractori statu epilepticu srse
short interest float
technolog clinic commerci valid challeng exist technolog mersana platform address
sever agent alreadi approv includ one see addit opportun categori
on-going dose-escal studi key class toxic monitor
mrsn second program target valid target talk potenti opportun program
approach partnering/strateg collabor
breast cancer higher ph interim data expect
breast cancer low post kadcyla ph expans cohort
data expect
short interest float
sitravatinib mechanist compar ret/trk inhibitor develop cabozantinib vandetanib specif one molecul rxdx
would handicap argument respond seen sitravatinib plu opdivo combo could either pseudo-progressor late respond earlier therapi
hdac inhibitor mix develop histori give confid target molecul differenti other
clinic collabor azn evalu mocetinostat azn inhibitor durvalumab non small cell lung cancer nsclc potenti solid
tumor speak scientif rational combin develop plan
take advantag new fda guidanc develop agent across tumor type
sitravatinib ret cbl nsclc nd line ph ib data updat
sitravatinib nsclc combo w/ opdivo ph ii updat data like
mocetinostat hdaci nsclc combo w/ durvalumab ph i/ii initi data
short interest float
see copaxon market evolv impact mp gener price assum addit gener enter year
im glatopa hasnt lost lot share even enter signific price eros see market shape
give us updat humira eylea orencia biosimilar latest statu product
give us flavor novel drug pipelin valu proposit asset highlight clinic mileston occur year
glatopa approv chang momenta cost control biosimilar invest strategi
initi pivot patient studi aflibercept eylea
initi phase proof-of-concept studi anti-fcrn
identifi potenti collabor partner file bla biosimilar humira
short interest float
attende simon moroney ceo ank linnartz vice-president ir head corpor
tremfya launch royalti right
tremfya royalti rate chang differ revenu level royalti sale market
dlbcl
target target car-t program pro con use antibodi compar car-t one compromis
next step expect replac antibodi b-cell malign pivot trial strategi
fc-engin modif sort dose frequenc expect
myeloma
antibodi formerli partner celgen similar differ darzalex sanofi isatuximab
futur schedul weekli dose
outlin fda agre dlbcl develop plan dlbcl
final phase i/ii result myeloma
phase develop strategi myeloma
clarifi develop plan atop dermat
cll phase ii result
david garrett vice-president corpor control head ir
remind us lefamulin discov believ drug clinic profil render ideal product commun acquir bacteri pneunomia
design second pivot trial differ first would character risk profil studi
attribut oral lefamulin compar characterist iv lefamulin
lefamulin succeed second phase remain track regulatori action remain gate factor nda file term safeti databas
much valu lefamulin potenti lie oral formul nbrv well resourc enough capit valu product outpati set
need
short interest float
analyst daniel antalffi medic suppli devic
new ceo strategi new ceo attract neovasc opportun top prioriti next month what view mitral valv
market role transcathet mitral valv play vs repair assess neovasc opportun envis compani year year year
capit need nvcn capit structur look like current burn rate reduc conserv cash cash hand
receiv fundrais pay novemb long cash posit fund daili oper necessari clinic trial
tiara mani patient implant date mani implant center momentum seem build enrol last quarter
current quarterli enrol rate base current expect enrol rate long anticip take enrol patient ce mark trial
mitral competit landscap number differ valv develop manag view competit landscap market support
reduc progress made possibl partner reduc could partnership look like growth trajectori manag expect
tiara trial total number implant reach patient
cosira ii trial nvcn expect enrol patient
tiara ii ce mark trial center approv nvcn plan enrol patient
short interest float
could reimbursement/access dynam ingrezza chang year formal payor decis made way could impact product uptak
rapid pace ingrezza launch chang way think peak sale potenti tardiv dyskinesia td market simpli develop faster
type patient earli adopt ingrezza would character demand across mood disord versu schizophrenia
think season could play ingrezza launch respect patient demand payor dynam donut hole
speak on-going dynam capsul versu ingrezza capsul proport patient seem stay chronic
talk rational increas valbenazin dose on-going tourett studi look tetrabenazin efficaci td versu tourett higher
dose requir latter indic evid
proof concept data
short interest float
analyst seamu fernandez
discuss market opportun brolucizumab wet age-rel macular degener entri market year today might evolv
subset analys lesion type size eager present might see result
discuss evolv increasingli crowd market agent new market entrant impact formulari discuss much impact
expect class cosentyx secukinumab antibodi
youv discuss approach value-bas price agent kymriah car-t pediatr acut lymphocyt leukemia ilari
canakinumab cardiovascular cv risk reduct see strategi grow evolv nv drug across industri
market entresto evolv us vs global might paragon studi entresto hf-pef heart failur preserv eject fraction chang
uptak drug posit upcom interim look
discuss opportun import label discuss fda relev impact drug wake ocrevu impress launch
two three agent excit see data end success believ potenti transform nv
top-lin data phase trial kisqali ribociclib inhibitor
hormon receptor posit hr breast cancer
pdufa date kymriah car-t diffus larg b-cell lymphoma dlbcl
tafinlar adjuv melanoma aimovig erenumab anti-cgrp antibodi migrain
eu regulatori decis aimovig kymriah pediatr dlbcl
tafinlar mekinist biosimilar humira neulasta remicad
potenti interim analysi entresto paragon trial heart failur preserv eject
fraction hfpef final readout
short interest float
analyst seamu fernandez
insulin price could help us understand rel price us europ part world differ impact lli basaglar insulin
price see increment pressur sni op admelog us
stabil price pressur diabet realist class rel safe price pressur affect class big concern
see class ozemp potenti oral market confid class like avoid progress toward
exclus formulari seen prandial basal insulin
sustain data ozemp impress plan use clinic dataset sustain engag payer physician launch ozemp
tresiba nvo achiev market share goal product speak littl bit market dynam tresiba us label updat
sever hyperphosphatemia affect adopt plan promot tresiba us post-label updat
see ozemp victoza co-exist longer term uptak product ramp market messag go promot
once-weekli
phase data oral semagultid agonist type diabet
us regulatori decis tresiba label updat
ozemp once-weekli semaglutid regulatori decis europ japan
result lli cv safeti studi rewind trulic
phase cv safeti data oral semaglutid agonist
market cap dkk
short interest float
phase iib endometriosi studi fulli enrol level pain reduct would constitut success major thing want learn studi
term dose without addback advanc phase
initi data came studi done japan homogen heterogen endometriosi reason expect us/eu popul would
differ
term potenti competit think mp /nbix op elagolix myov regulgolix differenti product
obseva current think import avail dose without add-back think drug develop approach differ
compani space
phase ii found nolasiban work less well patient high progesteron level mechan behind
short interest float
xhanc indic nasal polyp dynam market unmet need think xhanc fit current treatment
fda grant approv xhanc septemb launch product plan remind us reason delay launch initi
optinos prepar launch
payer side payer discuss go xhanc give us sens see coverag tier placement product shape
chronic sinus indic next step xhanc initi trial think market xhanc could potenti first drug therapi
approv patient current treat
next develop pathway exhal deliveri technolog medic think util therapeut area might
go next
initi chronic sinus trial xhanc
short interest float
stephen tang chairman board director
growth opportun molecular genotek busi saw solid growth busi last quarter albeit plenti season expect
growth given backdrop talk us addit opportun see ahead
self-test market help us understand view hiv self-test market long-term growth opportun ahead
asia asia growth driver also could elabor mix revenu opportun see
microbiom busi microbiom busi appear pick small base could elabor us opportun see long-term
expect long-term
gross margin gross margin came lower quarter appear influenc factor could elabor expect gross margin
year put take could remind us
short interest float
antibiot launch past year gener slow requir lot resourc launch omadacyclin differ
multipl drug approv skin infect gener avail pneumonia what unmet need two omadacyclin market
light recent failur oral formul ttph eravacylin anoth tetracyclin uti think potenti omadacyclin uti
key similar differ eravacyclin omadacyclin
sort drug exposur gener omadacyclin urinari tract
think competit threat nabriva op lefamulin member new class could drug market advantag omadacyclin
short interest float
advantag disadvantag util anticalin protein therapeut
bispecif compar program develop
view cancer landscap see posit
strateg rational behind recent partnership
phase first-in-human data
phase initi safeti pd data
short interest float
see mad data cystic fibrosi cf compar kalydeco orkambi
regard futur develop cf think potenti collabor and/or posit combo therapi
market opportun leber congenit amaurosi type competitor differenti
briefli comment axiom edit oligonucleotid eon platform led recent collabor glpg
lastli seen dystroph epidermolysi bullosa deb current standard care competit landscap look like
dose first patient studi deb
data evalu lca
first readout part studi deb
data evalu lca
second readout part studi deb
posit ph ib mad data cystic fibrosi link
short interest float
cso head research develop marci nanu svp ir rebecca john
proprietari oral peptid platform goal technolog choos lead program
recent result ulcer colitis/uc improv upon vedolizumab
given numer agent uc space step take ensur smooth enrol progress uc trial
led partnership crohn diseas recap term deal us
target iron overload disord agent develop
earli interim updat uc
top-line data uc
top-line data crohn diseas
ind submiss iron overload disord
short interest float
program on-going link partnership favor link underappreci program report posit data link
recent data amplifi corrector potenti
think tripl combo program compar glpg patient subgroup cf target
pti tripl combo therapi timelin compar glpg strategi get market fast
recent endors develop network us clinic trial network eu help execut trial
compani vision beyond tripl combo therapi what next
poc result kalydeco patient amplifi cf
poc result orkambi patient corrector cf
poc result cf patient cf
initi cf patient cf
poc result cf patient cf
short interest float
like benefici pt advocaci group endors us eu link data program provid encourag pti tripl combo therapi link
head commun
walk us clinic develop strategi provid context think phase iib pronto studi read
phase vital studi
walk us regulatori strategi base posit pronto studi result think fileabl us
review data lend support use nt-probnp biomark al amyloidosi
purport mechan action
potenti treatment parkinson diseas collabor roch see phase ib mad support move
phase ii select patient phase ii pasadena studi expect learn pasadena prepar possibl phase program
initi phase studi attr amyloidosi
short interest float
nerlynx posit extend adjuv set especi recent approv roch perjeta adjuv set
current fda label nerlynx compar perjeta early-stag adjuv popul
current prescript trend look see preferenti usag drug certain subgroup like node hr
feedback receiv nerlynx side effect commerci set particularli grade diarrhea rate
updat statu phase nala trial metastat set
neratinib breast cancer extend adjuv chmp vote feb
neratinib breast cancer line metastat ph nala top-lin data
short interest float
custom satisfact compani recent best award improv physician product physician categori cite
improv made custom support increas client satisfact see term client satisfact client attrit drive
usabl separ best award recent data show provid survey feel respons drive improv usabl commentari
earn januari suggest usabl satisfact focu upcom updat govern requir fulli satisfi
product plan improv custom workflow improv usabl score
eagledream eagledream recent receiv highest score popul health product captur best award addit disclos
earn sold eagl deal would character market demand popul health product gener eagledream recept
provid eagledream offer see eagledream help drive book growth futur
salesforc attrit would character re-ramp salesforc follow signific salesforc turnov manag team learn
experi use help continu turn-around busi
willing sell sever month ago specul qsii explor potenti sale would character open sale
recent acquisit entrada eagledream affect thought process prospect
book trajectori expect q/q growth y/i growth
new/upgrad product releas spring fall
short interest float
new leadership team seem effect retain client correct issu softwar develop new solut
first quarter first quarter public compani tell us bit simoa platform opportun ahead benchtop box
market
research market strength number life scienc tool compani report strong growth across board biopharma academia give us sens growth
see market simoa sens weather year-end budget flush
sr-x earli feedback recent launch benchtop instrument call sr-x could give us sens earli feedback custom sr-x sinc launch
launch on-going
sensit -- would like talk bit sensit platform make uniqu relev research long-term diagnost
 fund alzheim research fund seem better turn despit continu resolut what growth expect nih research
could outlin us what opportun see neurolog research given one area earli success alreadi
alzheim research fund increas could lead increment simoa placement given
launch hd-x could lead upsid system replac floor-stand
public lead awar simoa increas adopt platform
rel competitor
long-term basi penetr diagnost market repres greater opportun
roadmap broader adopt
short interest float
market attract featur market despit increas minim invas procedur despit fact hasnt
major innov space last yr
mosaiq us bit platform make uniqu revolutionari mosaiq view vs compet platform market
field trial what statu field trial europ us elabor us involv type studi data need
mileston mileston ought look thru year mosaiq readi market
ortho clinic us partnership ortho clinic diagnost help drive product market
complet field trial
launch mosaiq platform eu
short interest float
cfo elhan webb cfa head ir extern commun fudukidi
anabol market declin last four year believ entri revers declin
market share expect brand forteo potenti gener forteo
percentag us patient access tymlo year-end commerci govern plan forteo still prefer account
lilli rebat affect respons launch lilli re-invest promot forteo respons tymlo launch
tymlo chmp decis expect compani confid european approv
transderm patch version tymlo type inform develop process investor receiv januari fda meet
eu tymlo partnership use financ event compani interest profit share royalti would partner patch well
differ select estrogen receptor degrad serd develop
respons rate durat respons requir phase ii trial metastat er breast cancer pivot studi registr
tymlo commerci result market dynam year
tymlo transderm patch regulatori updat januari fda meet
elacestr phase ii metastat er breast cancer single-arm monotherapi trial design
tymlo eu regulatori event partnership
short interest float
catalyst trial highli power detect treatment arm primari outcom chang baselin wk howev think
benchmark requir approv fda
elabor safeti hyperfiltr controversi surround bardoxolon use chronic kidney diseas ckd especi context recent
cardin tsubaki data
remind us exist data support statist signific retain benefit estim glomerular filtrat rate egfr week discontinu
data evalu safeti and/or efficaci bardoxolon ckd patient exist
fda accept mfar appropri primari endpoint approv moxi trial comment fda would like see statist
signific improv mfar compar previous report part
larg volum primari research emerg past decad identifi dysfunct mitochondria contribut etiolog numer diseas
result motor part trial mean expans product portfolio
part top-line data motor trial
top-line data lariat trial
top-line data catalyst trial
top-line data phoenix trial
short interest float
initi link posit data support bardoxolon ckd link link
vector develop expect safer efficaci previou gener vector
talk littl bit licens agreement set use vector
dr jame wilson recent decid step chair solid sab cite emerg concern possibl risk high system dose aav know
refer reflect aav develop lab
anti-vegf therapi close compar learn gene therapi studi done wet order
design program success
would character need patient mp disord beyond ert address
late top-line data wet age-rel macular degeneration/wet
late top-line data homozyg famili hypercholesterolemia/hofh
enrol mucopolysaccharidosi type i/mp
enrol mucopolysaccharidosi type ii/mp ii
latest updat link
short interest float
lead asset compar structur anti-mir platform relev alport syndrom autosom
comment diseas modifi effect observ preclin clinic set expect see term result
hera studi evalu alport syndrom
goal alport syndrom program commerci posit program opt-in sanofi sni op elabor
partnership sni result would like see order consid opt-in
type patent protect exist specif comment diseas state type patent held length
rgl cash runway look like compani plan fund clinic program futur
short interest float
initi link clinic stage kidney program support promis preclin data
diversif portfolio toni lead diversif compani past year lay us bit detail strategi took custom
diversif follow expect growth
spectrum acquisit let talk acquisit done space start spectrum filtrat pivot one
growth driver spectrum look like number thing mab vaccin gene therapi shouldnt spectrum grow better go forward
hand
 attract potenti areas/seg downstream upstream continu look term expans product uniqu set
technolog area think could enhanc growth profil add diversif
growth rate see xcell atf expect long-term fit spectrum
asia could describ us effort asia addit larg spectrum
short interest float
sparsentan focal segment glomerulosclerosi fsg provid insight whether fda want see decreas proteinuria egfr
would satisfi decreas proteinuria stabil egfr
differ unifi parkinson diseas rate scale updr endpoint use compassion use program vs pantothen kinase-associ
neurodegener activ daili live pkan-adl endpoint use ph fort trial
aspect open-label compassion use program give confid pkan obtain fda approv fort studi
aspect sparsentan propos mechan support pursuit iga nephropathi
life cycl manag strategi current work thiola
resubmiss trial protocol fsg
initi sparsentan trial fsg
rtrx base busi continu grow pipelin progress link
short interest float
one case signific sedat phase program think home infus model brexanolon feasibl critic abil dose home
capit market potenti product
speak recent chang made trial post partum depress could studi serv pivot
regard mdd kind long term efficaci data requir approv depress drug like ssri snri etc approv kind
drug need prove effect durabl beyond placebo-control trial
think possibl explor re-treat phase
think risk toler and/or abus liabil
what clinical/regulatori path insomnia might futur trial compar design one
brexanolon file nda
initi studi bipolar depress
short interest float
analyst seamu fernandez
given import free market price genzym busi what new differ convers past year genzym uniqu well posit
debat rare diseas portfolio vulner go forward see multipl sclerosi still protect therapeut area
see ms space evolv ever increas number treatment option includ roch ocrevu ocrelizumab impact opportun
lemtrada well oral therapi aubagio see sni commit ms evolv year ahead pipelin asset uniqu
excit
discuss pace dupix uptak percentag us opportun youv alreadi reach see chang next month
might start see real earn leverag emerg
recent acquisit bioverativ restructur mp allianc backdrop view evolv competit landscap hemophilia
respect agent roch hemlibra eventu gene therapi market might compar given posit view threat potenti
beyond caplacizumab acquir ttp broad opportun see nanobodi platform acquir ablynx
beyond squamou basal cell carcinoma cemiplimab gain meaning share increasingli crowd marketplac
result odyssey outcom trial praluent alirocumab inhibitor
hypercholesterolemia
result pivot phase trial cemiplimab basal cell carcinoma
result phase trial dupix dupilumab nasal polyp
result phase trial isatuximab relapsed-refractori multipl myeloma
short interest float
drive forc behind exondi exon skip-amen duchenn muscular dystrophi dmd commerci strength/success
current understand clinic meaning level dystrophin product dmd boy
provid us updat essenc exon skip-amen dmd boy studi
rational behind select microdystrophin nationwid genethon gene therapi candid
peptide-conjug phosphorodiamid morpholino oligom ppmo efficaci safeti signal see preclin given evolv understand
clinic meaning dystrophin level hope demonstr first ppmo studi
fda regulatori updat golodirsen exon skip-amen dmd
short interest float
commerci strength expect continu link better efficaci higher toxic ppmo link
valu proposit lead product furoscix unmet need market target
potenti risk see upcom pdufa date june
incent variou stakehold involv treatment heart failur patient take us physician patient nurs hospit
payer would think trade-off use furoscix versu current standard care
us health econom studi process conduct expect like start see earli adopt drug
addit see peak sale potenti furoscix
product pipelin beyond furoscix
pdufa date furoscix june
link scpharma initi report link
short interest float
investor think potenti trajectori adcetri front-lin hodgkin lymphoma pend approv
potenti market opportun adcetri matur cell lymphoma mtcl
regulatory/clin efficaci bar enfortumab vedotin checkpoint inhibitor refractori urotheli cancer patient
gate factor start pivot studi tripl neg breast cancer tnbc
adcetri data line matur cell lymphoma
preclin sea-bcma data
short interest float
analyst daniel antalffi medic suppli devic
on-going eversens eu launch strong end year annual think sale ramp increment driver
adopt mani countri cover point increment countri add expect
upcom eversens launch latest updat fda approv time whether panel like eversens there panel launch
still track point
capit need addit capit recent convert note offer current cash take requir capit
like avenu youll pursu expect revenu run rate get cash burn break even margin profil compani
point
competit landscap manag view market dynam mdt abt libr continu roll-out like launch
patient switch perspect percent patient ad europ prior cgm user continu glucos monitor cgm
reason believ wont see trend eversens launch
product pipelin time key new product launch includ eversens pediatr type product next month
key data releas tap
eversens fda approv product launch expect
eversens xl ce mark receiv eu roll-out on-go trial expect initi
short interest float
overal thought multipl myeloma landscap car-t see car-t program posit
compar target vs target pursu car-t multipl myeloma bcma
talk potenti car-t earlier line treatment multipl myeloma
think priorit posit car-t antibodi drug conjug program
busi develop strategi move forward
car-t ind file phase initi
ind file
resinferatoxin ind file osteoarthr pain
short interest float
attende stephen webster cfo ryan asay head ir
prepar commerci launch luxturna inherit retin dystrophi due biallel mutat mani center launch initi
adopt innov price model luxturna work payor
hemophilia need occur transit complet
key threshold youd like achiev hemophilia gene therapi see initi data among patient treat hemophilia
also guid data updat choroideremia patient reach post-treat mark investor expect
commerci launch luxturna inherit retin dystrophi due biallel mutat
us
data updat choroideremia
ema approv voretigen neparvovec
data updat hemophilia
transit hemophilia
short interest float
first gene therapi approv link goal hemophilia link updat link
approv ibs-c indic expand market opportun trulanc
walk us initi sale forc market side done trulanc expand new indic ibs-c
see prescript constip market shape two entrench product linzess amitiza space make trulanc stand
among competit
give us updat contract trulanc coverag current stand today expect evolv
plan introduc trulanc ou market latest statu
sale ramp trulanc ibs-c chronic idiopath constip cic
short interest float
synthet biotic differ program target microbiom
remind us saw urea cycl disorder/ucd liver cirrhosi second studi ucd know
dose use move forward
strategi pursu liver cirrhosi elev ammonia differ ucd pursu indic
studi design primari endpoint phenylketonuria/pku see fit market especi pegvalias horizon
beyond inborn error metabol metabol diseas indic area pursu partnership help accomplish
initi second studi ucd
initi studi liver cirrhosi elev ammonia
interim data liver cirrhosi elev ammonia
initi sad/mad hv pku pt pku
interim data pku
short interest float
posit data derisk sybx proprietari platform link partnership could expand sybx platform link initi link
approv tell us whether still pace approv anyth anticip could chang timelin day
data differenti part data surpris data anyth think stronger weaker earlier
contract clarifi mani contract total right number high-risk patient address think translat
adopt expect
sale process could elabor sale process evolv think term launch sale process us
international/europ provid us color intern revenu number account ce mark help europ would
expect adopt faster
fda approv expect
launch lyme expect
short interest float
recent host investor event recap main takeaway market opportun manufacturing/cog value-bas price
takeaway amgn fourier data implement lesson outcom studi
also explor inclisiran hypercholesterolemia heterozyg homozyg famili hypercholesterolemia hefh hofh respect current
program
base number studi plan inclisiran latest guidanc opex head
remind us recent transact mlnt econom mlnt
enrol complet atherosclerot cardiovascular disease/ascvd
studi inclisiran hypercholesterolemia
enrol complet heterozyg famili hypercholesterolemia/hefh
studi inclisiran
first patient dose homozyg famili hypercholesterolemia/hofh
studi inclisiran
nda submiss inclisiran
short interest float
melinta transact link enrol suggest unmet need ldl-c lower drug link investor day takeaway link
compani lead product candid dual combin engin viru prodrug differenti therapeut approach oncolog
gene therapi approach glioma histor face sever hurdl forese approach overcom
phase data disclos date compar histor control approv drug
recent clinic data shown certain genet molecular marker associ favor overal surviv os glioma patient idh mutat
associ favor prognosi view genet marker
last quarter compani announc updat protocol on-going trial recurr high grade glioma summar key protocol chang
fc phase interim recurr hgg
fc phase ib preliminari result solid tumor
short interest float
posit senhanc -- initi procedur target area target robot institut vs non-robot institut
first new entrant abdomin surgic robot nearli two decad competit space intuit long monopoli
surgic robot market talk competit dynam play plan carv run lane
youv made signific progress last month transit develop commerci senhanc approv octob
give us updat earli commerci effort gone sale forc ramp go feedback hear back
capit cycl rep alreadi field
procedur indic beyond current gyn colorect procedur alreadi approv plan target next submit yet
gallbladd and/or hernia indic fda long anticip regulatori approv process addit procedur
advanc instrument side work us approv -- advanc energi articul instrument instrument timelin
expect
intern describ kind success youv sinc fda approv notic shift recept platform sinc
indic expans addit procedur
us launch addit instrument senhanc system instrument advanc
short interest float
cancer type like respond inhibit tumor type macrophag driven other
learn competitor target agent develop
two target agent differ
seen date intratumor phase studi patient ctcl next step ctcl
plan evalu combin checkpoint inhibitor
phase data
short interest float
burosumab x-link hypophosphatemia/xlh pdufa date april us recap fda told assess data ped
pre-commerci plan progress latin america find region potenti growth other
pre-commerci work prepar launch burosumab xlh us assum approv
commerci mepsevii go
safeti see over-the-counter defici result particularli elev liver enzym patient peak iu/l see
market consid phenylbutyr ravicti avail
earli ema decis burosumab xlh
april pdufa burosumab xlh
data burosumab
eu chmp opinion vestronidas alpha mp
interim data over-the-counter defici
short interest float
po eu chmp decis link posit xlh data link ahead pdufa mepsevii approv link encourag data gene therapi link
statu manufactur capac much hemophilia market expect address time receiv approv
walk us thought process behind recent strateg move use padua variant acquir ip
remind us clinic trial plan purpos lead-in studi
level factor ix activ think optim eye patient physician fda
huntington diseas hd program differenti program data gener thu far
submit amend ind hemophilia
initi studi
ind file huntington diseas
top-line data initi patient studi
updat congest heart failur chf program partner
short interest float
establish proof concept hemophilia gene therapi incorpor hyperact padua variant could deliv appeal product profil
volum track across acut behavior impact strong flu season
updat behavior length stay return normal behavior revenu growth still achiev
updat acut trend observ stay convers chang normal revenu growth target
could manag quantifi tax reform tailwind provid color capit deploy opportun tax reform tailwind
updat govern investig oper fallout time offic inspector gener oig settlement
earn guidanc sustain industri lead acut trend
return normal behavior top-lin growth length stay stabil
acut volum track color around strong flu season
capit deploy opportun tax reform tailwind
oig settlement possibl
short interest float
top facil valu pick see weak behavior fundament length stay bottom return top-lin growth
afirma penetr could updat us market penetr afirma gain could continu deliv volum penetr mind
lower guid expect help everyon get page factor drove lower guid guid
year think address includ oper challeng behind transfer gec gsc
quest/ameripath agreement elabor much quest agreement could contribut also expect impact asp
econom deal sort assur co-promot work end make sure success relationship
cover contract live provid us updat number cover contract live test
envisia key mileston year envisia see launch shape beyond coverag decis medicar
percepta anoth growth vector slow adopt
quest/ameripath could drive increas revenu
short interest float
maci adopt full quarter launch talk anecdot feedback maci adopt right multi-year growth trajectori product
base underli market opportun current penetr exist sale coverag chang maci previously-commerci carticel
epicel epicel strong mid-singl digit growth realiz much volatil busi think sustain long-
competit landscap competit landscap maci epicel crowd market competit differenti
compani retain competit edg competit product pipelin warrant attent
profit revenu run rate expect achiev sustain profit cash hand get discuss margin profil
maci epicel see gross oper margin go lever beyond gross margin drive oper margin expans
ixmyelocel-t strategi fda ask one studi support approv strategi activ seek strateg partner point
time feel compani bandwidth undertak addit trial pursu commerci product either way expect updat
product near-to-medium term
ixmyelocel-t besid ixcel dcm dilat cardiomyopathi studi least one
ixmyelocel-t trial requir fda approv time tbd
short interest float
big market sexual function improvement/vagin laxiti think long-term sustain growth rate aesthet medic devic product like
us ww
rf technolog differ laser technolog treatment vagin condit vivev uniqu posit market vs competit
rf product laser product
viveve-i chang convers custom around utilization/adopt genevev compani vivive-ii clinic studi expand compani
and/or acceler adopt technolog estim time around viveve-ii clinic program
signific would sexual function label term drive increas adopt categori and/or differenti vivev competit
vivev strategi address urolog stress incontin requir clinic data standpoint
approv viveve-ii
on-going progress stress urinari incontin clinic initi
short interest float
hcit budget look vs care coordin receiv bigger slice pie attent hospit cio
strong year face tough comp think growth stage come
happen intern front growth catalyst greatest near-term opportun
competit landscap current given live mani facil see provid push singl electron medic record care
coordin solut
talk cross-sel opportun vocera extens healthcar engag size term number common custom
see demand commun rural hospit market
think might penetr navi forc facil process separ compar armi deploy
contract announc major health system va dod potenti
penetr armi facil entri navi forc
himss confer march potenti contract product announc
short interest float
account rule caus move revenu prior period caus top-lin growth dampen howev core remain healthi
discuss mechanist rational behind vy-aadc
phase ib studi placebo arm given placebo effect parkinson signific render confid result offer real evid
walk us phase ii design power assumpt context phase ii result
given need surgic intervent confid abl enrol placebo-control trial vy-aadc
think potenti price reimburs model vy-aadc assum phase succe assumpt youv laid
what next candid vygr pipelin could see proof-of-concept data
short interest float
well understand type stereochem modif purif matter pharmacokinetic/pharmacodynam pk/pd oligonucleotid
patholog huntington diseas hd span whole brain point confid gener suffici drug exposur across brain knock
htt protein area pathogen
hope learn upcom roche/ion mp present httrx level htt knockdown would find encourag
wve hd antisens approach differ ions/roch
huntington diseas well understand risk associ inhibit translat healthi wild-typ protein
short interest float
size commerci opportun
reason confid system lupu erythematosu opportun
bispecif antibodi platform compar platform space
recent disclos plan develop product candid make interest target
advanc partnered/out-licens agent develop econom partner
phase initi
seek advic ema earli
sle phase ii initi data
aml phase data
 cell malign phase data
short interest float
walk us rational led strateg reposit decis pursu second gener inhibitor prader-willi syndrom
despit sever advers event sae associ beloranib use drug efficaci favor alter metabol profil pw patient though limit
preclin data thu far compar beloranib term efficaci
compani posit away thromboembolic/sa stigma associ inhibitor
also second gener inhibitor diabet differenti approv therapi
expect see ph data releas
much data need gener order suffici de-risk safeti perspect regulatori pathway
top-line ph data readout
short interest float
zfgn hire veteran ceo bring compani back rare diseas game link
attende samantha du ceo jonathan wang vice-president head busi
analyst seamu fernandez
larg niraparib opportun ovarian breast cancer china competit landscap look like china regard parp inhibitor
plan expand niraparib develop tumor type lung prostat cancer
likelihood view expedit pathway approv omadacyclin base pk bridg studi plu already-complet phase studi paratek
current antibiot market china compar us eu see omadacyclin fit
give confid brivanib clinic success hepatocellular carcinoma given drug failur two separ phase trial
fugan proof concept data talk us opportun china ph develop plan china perhap outsid china
investor think zlab corpor strategi option offer manag deep develop expertis china global ambit well
intern develop asset focu zlab
initi phase niraparib studi ovarian cancer brca breast cancer china
estim readout phase trial brivanib treatment advanc china
result phase trial fugan patient eczema china
launch niraparib hong kong macau month ema approv
short interest float
discuss design time phase glepaglutid analog trial short bowel syndrom sb
market opportun sb current treatment advantag glepaglutid offer exist therapi
given ultra orphan statu congenit hyperinsulin expect price around dasiglucagon indic
advantag hypop dasiglucagon rescu pen comparison current glucagon kit expect expand market hypoglycemia
discuss challeng associ creat dual hormon pump dasiglucagon overcom
initi phase trial glepaglutid analog sb
report phase result dasiglucagon glucagon analog hypop rescu pen
initi phase trial dasiglucagon dual hormon pump
initi phase trial dasiglucagon congenit hyperinsulin base safe-to-proce
letter
announc next intern drug candid clinic develop
short interest float
regard second dravet phase studi patient background stiripentol anyth fundament differ patient popul
versu enrol first dravet phase
concern potenti cardiovascular cv risk fda said matter kind precaut taken clinic
case mild regurgit emerg open-label extens studi would problem approv and/or commerci potenti opinion
point what threshold safeti becom problemat opinion
what exclusivity/ip posit see potenti upsid orphan drug exclus
think evolut commerci dynam cbd cannabidiol market could use combo
complet phase lennox gastaut lg studi
short interest float
valuat next month believ share trade appli ev/sal multipl
estim assum current multipl sale sustain believ sustain strong double-digit growth profil profit
warrant premium repres uniqu asset increasingli volatil market strong track record out-performance clear pathway earn upsid
strong balanc sheet cash end quarter debt
risk valuat risk rate valuat includ failur drive increas util rate and/or continu add new account steadi
rate failur execut pipelin launch new geographi potenti reimburs declin potenti competit pvad product
secur approv gain meaning market share potenti product recal
valuat aciu estim price target aciu month use dcf analysi dcf valuat employ discount rate
termin growth rate higher rang phase biotech compani coverag univers aqxp reflect encourag
nonetheless statist success crenezumab data base case assumpt anticip peak royalti base royalti rate
risk-adjust odd success aciu three therapeut program assign valu anti-tau partner roch use
probability-of-success partner janssen use probability-of-success wholli own product use
probability-of-success current valu ac immun diagnost platform could repres addit upsid diseas modifi agent attain
risk valuat ac immun high risk invest investor aciu face multipl risk includ limit clinic risk crenezumab
examin phase trial phase ii data show trend statist significanceclin risk anti-tau antibodi earli stage vaccin candid
pursu unproven target and/or unproven therapeut strategycompetition/commerci risk alzheim compet
program mani big pharma/biotech playerscollabor risk roch partner may return right licens program ac
immunedilut risk model chf equiti rais believ could impact stock significantli
valuat price target base npv methodolog assign probabl success po luspatercept rs esa-
refractory/ineligible/intoler md esa-na md md subpopul also assign po luspatercept transfusion-
depend -independ beta-thalassemia respect assign po candid sotatercept pah fshd deriv
price target discount probability-weight annual cash flow small/mid-cap biotech discount rate assum termin growth rate
cash flow beyond addit factor cash balanc
risk valuat risk valuat includ clinic regulatori commerci competit risk pipelin product lead product luspatercept
recent enter phase develop program remain rel earli stage therefor signific uncertainti exist development-stag
compani sever year away commerci launch also financ risk
valuat akao deriv price target akao month use mix revenu multipl dcf analysi discount rate
termin growth rate model gross us sale assum partnership akao receiv mid-double-digit royalti
also model gross us sale cuti small royalti royalti rate risk-adjust revenu use
probabl success reflect optim approv base posit data balanc fact full data yet releas
nda yet file discount rate rang compani coverag univers revenu multipl
slightli higher multipl use anti-infect peer nbrv reflect consolid natur opportun
believ could requir fewer sale rep launch
risk valuat investor akao face multipl risk includ limit risk plazomicin akao yet file nda
plazo nda could evalu advisori execut risk plazomicin launch us and/or includ reimburs risk
competit risk risk akao hope find partner eu territoriesmanufacturing/product risk akao reli third parti
manufactur manufactur site perform plazomicin quot fill quot step receiv warn letter februari risk
potenti equiti rais model equiti rais believ could impact stock significantli
valuat achn pt base discount cash flow dcf analysi incorpor variou complement-medi diseas pnh
current estim penetr estim pnh/ahu patient whose diseas well control op soliri
roughli treatment-nav pnh patient assum peak penetr coincid expir orphan drug exclus ode us order
account potenti gener competit also includ potenti revenu glomerulopathi geograph atrophi ga assign
probabl respect reflect earli stage develop achn complement inhibitor portfolio benefit extens patent protect
last whose extens could strengthen longev revenu stream pre-commerci compani appli discount
rate termin growth rate consist similarli situat compani coverag bold
risk valuat risk valuat includ competit risk product receiv approv enter commerci risk associ
clinic trial regulatori review
valuat valu price target base dcf valuat assum discount rate probability-adjust sale
profit appli termin growth rate valuat assum late stage probabl success po seborrh
keratosi sk po common wart contribut valuat assum po oral jak inhibitor program
alopecia areata sever form immune-medi hair loss disord contribut valuat
risk valuat invest involv combin differ risk seborrh keratosi signific risk view
commerci execut risk new product establish standard care also intellectu properti risk other potenti challeng
hydrogen peroxid method use patent and/or compound solut develop compani oral topic jak inhibitor
compani must demonstr efficaci safeti in-licens jak inhibitor chronic intermitt treatment immune-medi hair loss later
male female-pattern bald
valuat deriv price target base via dcf analysi use discount rate termin growth rate
rang commerci smid cap biotech/specialty/pharma peer mp akao op discount rate higher end
rang due pend ampyra generic associ risk parkinson model probabl regulatori approv
assumpt lead us peak revenu estim
risk valuat risk includ potenti commerci regulatori setback disappoint clinic data dilut potenti financ
earlier-than-expect emerg gener competitor sinc major revenu come one product aforement event could
impact stock significantli
valuat adap estim fair valu adap one year base probability-adjust multipl sale analysi attribut
ny-eso tcr assum probabl success depend indic tcr assum probabl success
rest net cash appli multipl product sale multipl royalti discount back period use wacc
discount rate similar small-cap biotech stock coverag tril
risk valuat adap face signific regulatori risk sinc product candid current earli stage preclin clinic
develop similar mani development stage biopharma compani adap also face manufactur competit commerci regulatori safeti
risk well risk intellectu properti adap also face financ risk dilut current sharehold sinc believ compani cash
flow-posit forese futur specif risk includ anti-canc activ achiev target may translat target
antigen potenti frequent target non-target relat toxic larger patient popul potenti increas competit adopt t-
cell compani kite juno blcm potenti difficulti transit manufactur process commerci scale
valuat price target share base dcf sum-of-the-part analysi longer includ includ
probability-weight sale mileston payment royalti nv mp partnership probability-weight mileston payment royalti
janssen biotech subsidiari op partnership assum po advanc prostat cancer po late-stag
lung cancer po cdn product melanoma head-and-neck cancer well po lymphoma assum discount rate
believ appropri given revenu project probability-of-success-weight termin growth rate also includ
substanti current cash balanc valuat
risk valuat safeti record live listeria cancer vaccin far still base small number trial patient cancer vaccin gener
high histor failur rate io space crowd gener listeria vaccin may suffici differenti efficaci altern dendrit cell-
target therapi io approach may less amen combin therapi io agent uncertain regulatori environ live
bacteria cancer therapeut uncertain futur revenu engin listeria product protect biosimilar competit patent expir
orphan drug protect end sting agonist yet demonstr activ human
valuat aldr estim price target aldr month use dcf analysi dcf valuat employ discount rate
termin growth rate middl rang biotech compani comp includ op gwph op share count
dcf includ option warrant estim convert prefer share termin growth rate base termin
year support view aldr revenu model come biolog may durabl model
risk-adjust eptinezumab revenu royalti base probability-of-success iv self-administr
anti-cgrp share iv share follow-on self-administr sq formul
risk valuat risk valuat includ fda/ema approv risk eptinezumab risk clinic program delay competit risk given
presenc multipl anti-cgrp antibodi manufactur risk risk disappoint clinic data intellectu properti risk on-going legal battl
teva risk dilut financ model addit equiti rais
valuat price target base simpl averag three approach believ reason
basi valu stock today approach simpl price earn multipl compar large-cap biopharma compani celg
growth adjust near-term earn multipl ratio discount cash flow dcf use rel multipl similar growth
compani ep appli ep estim alexion give fair valu stock use expect ep
compound-annual-growth-rate alexion period current averag ratio larg molecul large-cap biotech give ep multipl
discount multipl compress alexion appli ep estim give fair valu
final dcf use termin growth rate post give current valu averag three approach
month price target alexion stock
risk valuat risk view outlook valuat alexion includ major chang price reimburs coverag label
soliri compani main product today risk includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri successor complement inhibitor product final
brand gener competitor product soliri come market captur greater share caus greater market price disrupt current
expect futur outlook valuat would undermin opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop commerci new indic soliri beyond
neuromyel optica myasthenia gravi novel rare diseas medicin time horizon forecast
valuat valu share stand-alon basi base dcf wacc termin growth rate believ
wacc appropri consist discount rate use pharma co nv gsk reflect
plan de-lev balanc sheet time
risk valuat risk valuat includ price competit pressur key market notabl botox cosmet botox migrain
success failur key pipelin product particularli ubrogepant/atogep oral cgrp antagonist relamorelin diabet gastroparesi rapastinel
sever resist depress earlier-than-expect loss exclus loe key brand
valuat price target month base probability-of-success adjust dcf analysi appli discount rate
termin growth rate similar peer oligonucleotid compani coverag also transit commerci stage compani
model reflect genzym sni opted-in fitusiran instead given larger potenti market opportun former
risk valuat invest fundament high-risk high-reward invest view may face signific scientif clinic
regulatori commerci intellectu properti ip competit manufactur risk import stock perspect clinic develop risk
associ patisiran possibl emerg innov competitor possibl safeti issu around rnai technolog may emerg larg number
subject treat extend period time believ could impact stock significantli
valuat price target inc base averag three approach believ reason basi
valu stock today approach simpl price earn multipl larg cap us eu larg cap biopharma stock azn sni rhhbi
gsk nv celg price sale multipl larg cap biotechnolog pharma compani novo celg discount cash flow
dcf use rel multipl larg cap biopharma compani ep appli ep estim give
one year futur valu use establish larg cap futur revenu multipl sale appli revenu forecast
give futur valu final dcf valuat base current outlook compani exist product probability-
weight revenu contribut late stage pipelin program discount compani wacc give fair valu today
averag three approach give price target
risk valuat risk view outlook valuat includ major chang label price reimburs coverag
compani legaci product failur compani growth portfolio achiev futur sale forecast risk includ develop delay
disappoint earlier stage pipelin asset earlier signific eros compani legaci product biosimilar innov competit
shortfal compani effort improv oper margin would also materi affect outlook valuat would larg dilut acquisit
therapeut area platform
valuat price target month base discount cash flow dcf analysi probability-weight sale use
risk valuat risk includ potenti disappoint clinic data regulatori setback commerci shortfal dilut financ sinc
present two late-stag product candid possibl setback may impact stock significantli
valuat aqxp deriv price target aqxp base blend dcf analysi multipl risk-adjust sale use
discount rate termin growth rate sale multipl consist biotech compani singl indic asset strong
ip runway year past approv nbrv assum probability-of-success balanc encourag phase ii data variou
uncertainti discuss risk valuat section
risk valuat risk aqxp valuat includ lack clear valid therapeut target potenti safeti risk dose week
potenti neg outcom phase potenti regulatori setback commerci shortfal due lack physician uptak reimburs challeng risk
dilut follow-on financ
valuat price target share base risk-adjust sum-of-the-part dcf analysi use
discount rate line risk-profil smid cap compani late-stag derisk asset believ tenapanor achiev market share
esrd-pi ibs-c indic respect
risk valuat tenapanor drive valuat clinical/regulatori failur would significantli impact valuat would clinic failur
inabl rais capit fund busi beyond
valuat rate share outperform pt shift focu away legaci product belviq weight-loss toward
proprietari pipelin innov medicin target cardiopulmonari gastrointestin gi indic could creat signific sharehold valu view
leverag biolog mechan valid garner attract valu ozanimod rcpt/celg op selexipag
atln/jnj op management focu smaller nich market also enabl compani independ pursuit commerci larger market
ulcer coliti uc could attract partner alreadi establish space longer term could introduc follow-on candid well execut
life cycl manag lcm strategi expand proof concept demonstr lead cardiopulmonari gi indic pursu
diseases/afflict share biolog mechan current assign probabl etrasimod uc extraintestin manifest eim
program pyoderma gangrenosum pg primari biliari cholang pbc ralinepag assign probabl pulmonari
arteri hypertens pah pain associ crohn diseas respect discount cash flow dcf analysi use discount rate
termin growth rate consist similar stage compani coverag achn
risk valuat shift focu proprietari pipelin risk associ clinic trial execut disappoint trial data regulatori
review commerci success relev meanwhil manag on-going effort divest/off-load belviq franchis could lead unfavor term
agreement may impact valuat
valuat arql estim fair valu arql share one year base discount multipl sale valuat appli multipl
probabl adjust us eu forecast arq product sale icca po proteu syndrom po use discount rate
consist valuat methodolog early-stag compani coverag adap iph tril
risk valuat earli stage biotech compani arql face extens clinic regulatori risk well manufactur ip commerci risk
arql also face execut risk financi risk estim arql current cash suffici fund oper compani may
addit financ need turn cash flow posit
valuat arri valu arri share month base discount cash flow analysi use discount rate similar
commerci near-commerci stage compani coverag termin growth rate appli probability-adjust
forecast binimetinib encorafenib selumetinib royalti
risk valuat emerg biotech compani arri face signific clinic regulatori develop risk well commerci risk arri
also face execut risk financi risk compani may addit financ need turn cash flow posit
valuat asnd deriv per share price target asnd month use discount rate termin growth rate price target
assum probabl transcon hgh approv pediatr growth hormon defici pghd lead peak risk-adjust net sale estim
addit model early-stag clinic pre-clin compound emerg platform gener addit revenu
begin peak risk-adjust net sale estim combin
risk valuat risk valuat includ potenti neg clinic competit regulatori fda surpris particular emerg
landscap biosimilar may limit premier price asnd inject signific technolog advanc develop longer-act version
inject biolog
valuat azn dcf-base price target azn appli pharma group azn gsk nvo nv sni discount rate
sale profit well termin growth assumpt
risk valuat risk azn includ worse-than-expect margin deterior blockbust gener competit failur durvalumab
immuno-oncolog tremelimumab immuno-oncolog overal surviv non-egfr mutant first line lung cancer mystic neptun studi roxadustat
hif alpha partner anemia acalabrutinib btk inhibitor cll dividend cut could occur extern revenu opportun
diminish
valuat next month believ share trade valuat appli ev/sal multipl
revenu estim assum basic stabl multipl current level estim compani get back track deliv
consist out-performance street estim move higher current level believ share deserv trade line broader small-
cap med-tech univers averag includ nxtm believ compani continu deliv given
stabl mid-to- high-teen sale growth outlook long-term mi come on-line potenti meaning sale oper synergi estech
ncontact acquisit close increasingli clear pathway profit beyond turn ebitda posit base
risk valuat risk includ failur success execut surgeon train new af indic drive slower-than-expect revenu
ramp slow open heart procedur growth and/or adopt concomit surgic ablat clinic trial delay failur receiv clearanc
next gen atriclip system ou regulatori delay ncontact integr
valuat bold bold leverag in-hous manufactur capabl har gene therapi potenti deliv cur therapi treat rare
ultra-orphan diseas bold program seek either improv upon current standard care pomp diseas introduc transform
treatment approv therapi exist light recent develop fda recept toward patient advocaci accommod
polit climat rare diseas drug believ bold could benefit expedit develop timelin wherea bold may first-to-market
gene therapi product believ compani strateg adapt lesson gene therapi frontrunn like op qure op
mp admittedli uncertainti surround payor would deem accept price gene therapi product may significantli impact
bold valuat howev drug deliv meaning improv standard care believ bold could garner price power rare
ultra-orphan drug either singl up-front payment pay-for-perform form payment mp pioneer method
luxturna drug valid bold gene therapi approach may also draw interest compani seek tap novelti gene therapi and/or
rare diseas space believ bold share best valu via dcf analysi use discount rate termin growth rate yield pt
risk valuat risk includ disappoint clinic data regulatori setback potenti dilut financ commerci shortfal sinc bold
product candid earli develop risk associ clinic trial well unforeseen issu may aris durabl shortfal higher pre-
exist neutral antibodi titer higher immun respons seen small clinic trial could impact stock significantli common
compani develop therapi orphan diseas true epidemiolog could also meaning implic market opportun lastli given
linger polit pressur drug price uncertainti surround payor coverag decis amount reimburs gene therapi product
one-and-don could pose signific risk compani busi model
valuat auph deriv per share price target auph share month base dcf analysi use discount rate
termin growth rate fulli generic revenu ascrib probabl success po voclosporin lupu nephriti ln
risk valuat risk auph primarili relat clinic develop voclosporin sinc auph one product pipelin data
qualiti time setback could impact stock significantli auph small cap biotech compani may need access capit market
financ risk also possibl
valuat pt support dcf translat ev/sal estim compar
select group quot ultra-high growth quot med-tech peer trade group includ
base ev/sal current trade group average vs howev believ bigger premium valuat
warrant given much faster top-lin growth prospect compound-annual-growth-rate vs peer sustain gm profil vs
average peer believ near- long-term estim conserv like leav room upsid note fastest grow
compani among high-growth peer group -- -sustain revenue growth rang gm forward
multipl rang view lend support use ev/sal multipl arriv target price
risk valuat potenti slower-than-project adopt curv adopt remain sidelin extend period hand surgeon
plastic surgeon perform trauma procedur surgeon tend slower adopt nerv repair technolog prefer trial new product
wait long term result dive develop degre product reorder take longer expect convinc middl
adopt clinical/econom valu proposit product could result flatter adopt curv potenti result risk estim new product
pipeline/market expans area could take time materi recent launch product pipelin product new market expans area still
develop could take longer materi current project model could mean downsid risk sale ep forecast
exposur regulatori risk pursu bla lose inher exclus avanc bla discret continu sell avanc
pursu bla could hamper compani abil enjoy uniqu commerci opportun potenti diminish believ
strong competit advantag could ultim lead competit allograft segment bake avanc revenu
project avanc market opportun furthermor guarante avanc bla success get approv repres potenti
regulatori risk result recon phase trial expect higher requir support bla could result higher expens
forecast assum model price pressur could put downward pressur sale gm forecast contempl certain degre
price pressur model moder gm time may experi signific price pressur estim assum could
put revenu gm forecast risk worse-than-expect price pressur could materi need discount greater degre
assum idn gpo compani tri drive bulk order larger institut valu proposit around portfolio avanc
axoguard aviv perceiv strong enough justifi current higher asp commerci execut risk compani unabl hire rep quickli
project take longer model rep come product curv could lead slower revenu growth trajectori
forecast likewis prove harder expect requir invest model open new account and/or drive deeper
penetr exist account could repres sourc downsid risk revenue profit forecast and/or lengthen oper leverag
prospect competit compet nerv repair busi unit part larger diversifi med-tech compani cross sell
capabl bigger resourc current nerv repair product compris small revenue larger competitor believ
market major focu compani howev compani increas investment/focu could result higher level
competit vs compani experienc past
valuat next month believ share trade -- previous -- rang dcf valuat
deriv base case upsid scenario supplement ev/fcf ev/ebitda analys ev/ebitda perspect valuat
right line group includ ew estim
risk valuat failur execut margin expans initi new product launch delay possibl acquisit either dilut perceiv
further baxter growth goal could pressur stock
valuat price target base simpl averag three approach believ reason basi valu
stock today approach price earn price sale dcf price earn approach appli current ep compound-annual-growth-rate larg
cap healthcar nv gsk rhhbi sni celg multipl ep forecast ep
discount result valu back one year compani cost capit one-year price target price sale approach use
current averag price sale slow grow larg cap biopharma stock nvo appli revenu forecast
price lastli dcf take present valu forecast annual free cash flow assum
valu termin cash flow base termin growth rate discount compani cost capit present valu
averag approach current one year price target
risk valuat risk view outlook valuat includ major chang price reimburs coverag label
compani exist treatment multipl sclerosi tysabri avonex plegridi tecfidera zinbryta success develop rapid market share gain
competitor product class success gener challeng tecfidera intellectu properti posit alter ahead expect
risk includ disappoint question result on-going trial import develop program particularli aducanumab
opportun better perform valu includ strong result mid-stag pipelin includ novel pain treatment raxatrigin anti-
lingo myelin restor program success progress compani co-develop alzheim diseas treatment eisai ban
valuat one-year price target per share pt base assign probability-of-success po lenti-d
ccald well po lentiglobin beta-thalassemia major account probabl respect sickl cell diseas
multipl myeloma car-t valuat base discount cash flow sum-of-the-part analysi use discount rate rather
typic use development-stag sinc includ premium valuat use termin growth rate
risk valuat face signific clinic regulatori risk sinc product candid current earli stage clinic preclin
develop like mani development stage biopharma compani also face manufactur competit commerci regulatori safeti risk
well risk intellectu properti also face financ risk dilut current sharehold sinc believ compani achiev cash-
flow break-even base current cash balanc may acquir premium add addit product candid pipelin current
reflect stock valuat
valuat next month believ share trade deriv appli price-to-earnings multipl
cash ep estim basic line large-cap med-tech group broadli top-tier sale growth profil
mid-to-high singl digit rang near-term ep growth profil line group think line multipl fair compani
continu deliv solid execut consist meet-or-beat quarter also ramp key new product move past litig issu see
opportun multipl expans ahead
risk valuat risk includ lack meaning recoveri med-tech market broadli major market drug-elut stent de
cardio rhythm monitor specif failur success execut key new product launch major litig loss potenti
product recal particularli within inabl suffici reduc cost drive oper margin expans
valuat dcf-base price target forecast cash flow use larg pharma discount rate termin
risk valuat setback key product notabl yervoy eliqui oral factor xa inhibitor anti-coagulation/thrombosi and/or clinic setback
nivolumab cancer immunotherapi nivolumab yervoy combin would pressur stock
valuat price target base blend dcf analysi dcf valuat revenu multipl
analysi p/w npv assign valu probability-weight p/w us sale rcc probabl success tnbc probabl
success melanoma probabl success assum royalti ex-u sale futur partnership also assign valu
probability-weight sale across sever solid tumor indic probabl success receiv profit share us
receiv ex-u royalti rang use discount rate termin growth rate
risk valuat pipelin program face clinic regulatori develop risk well commerci intellectu properti risk also
face execut risk financi risk addit may addit financ need turn cash flow posit
valuat stock trade ep estim histor ntm price-to-earnings averag
next month expect share trade ep would put stock use slightli lower multipl
valuat analysi due delay recogn accret cordi risk patient recoveri integr continu margin pressur
divis despit price stabil still face challeng price environ difficult sell-sid margin despit better perform medic
maintain mp rate due headwind includ brand gener price competit downstream sell-sid environ potenti
weaken volum due unravel piec hepat comp signific slowdown valu brand convert
gener next year
risk valuat competit intens custom concentr high compet op
mp well sever smaller medical-surg distributor includ owen minor mp inc mp result
competit custom buy-sid sell-sid may constantli tri pressur margin novat premier larg custom present
renew risk lose custom custom put signific margin pressur compani earn
could come pressur price could declin reform also pose risk price brand-nam drug gener declin time
margin could come pressur addit patient protect afford act health educ
reconcili act implement signific chang industri exampl increas rebat paid manufactur fee must paid could
advers impact buy-sid margin abl earn addit retail pharmaci face margin pressur due chang
medicaid reimburs chang awp could pressur compani sell-sid margin regul extens drug
distribut busi subject extens law regul cover mani aspect compani oper includ fraud abus law
prescript drug pedigre track mani requir mandat fda state feder law agenc
compani requir hold licens permit oper distribut center tax posit pose risk oper mani state
throughout world tax law complex within intern perspect addit ever refin lifo
account could advers impact compani report financi result inform system compani reli inform system
within corpor offic throughout distribut center technolog system complex requir facilit purchas distribut
thousand inventori line-item receiv process ship order manag bill collect process payment mani function
reason technolog system fail function properli earn could face substanti risk acquisit integr
could risk perform fair number acquisit past sever year may continu acquir futur
compani fail integr acquisit onto platform inform technolog personnel structur issu integr
process compani earn could risk concentr supplier pose risk supplier make revenu
five supplier gener compani busi contract typic written one-year basi automat renew year five year
given somewhat high degre concentr among manufactur depend honor supplier agreement
relationship end deterior manufactur put price pressur compani earn could risk
addit depend raw materi commod includ nuclear materi price oil impact distribut transport
cost econom trend compani global oper impact econom trend exampl recess could caus patient less
will go physician offic certain procedur done out-of-pocket cost could view substanti peopl unemploy
worri becom unemploy howev econom trend overal employ improv medical-surg distribut busi could improv
significantli transact exposur hedg
valuat price target appli ev/sal multipl estim reflect basic stabl sale
multipl sale estim discount small-cap coverag univers nxtm
given view underli fundament much intact believ share pois move meaning higher manag drive back
risk valuat risk includ increas sale forc disrupt competit atherectomi product gain market share potenti product recal
failur dcb drive atherectomi adopt
valuat celg price target celgen celg base simpl averag three approach believ reason basi
valu stock today approach simpl price earn multipl compar high growth larg cap medic product drug devic
compani present valu base price sale multipl peer coverag discount cash flow dcf analysi use averag peer
mature/end patent life larg cap biopharma compani rhhbi sni multipl consensu ep appli
ep estim celgen support one-year price target use exclus matur biotech price sale
multipl revenu appli revenu estim give fair valu lastli dcf use estim
compani current wacc appli period cash flow assum annual declin cash flow termin valu
adjust cash debt give present valu per share averag three approach current price target
risk valuat risk view outlook valuat celgen includ major chang price reimburs coverag revlimid
compani main product today risk includ commerci develop disappoint compani diversifi program otezla ozanimod
lastli challeng compani revlimid patent posit would view neg investor would larg dilut acquisit research
invest could undermin compani oper profit return invest capit opportun greater upsid current
forecast includ duplic earli clinic trial result ozanimod expand trial inflammatori bowel diseas success develop
commerci program compani collabor earli impress result acceler develop
compani antibodi durvalumab partner astrazeneca azn revlimid potenti lymphoma alreadi includ model
probabl success adjust basi better-than-expect result on-going phase trial suggest revlimid becom standard care
diseas would also offer signific upsid current forecast valuat
valuat ci primari valuat methodolog base rel price-to-earnings rel price-to-earnings track function compani histori
manag group averag assess potenti price-to-earnings expans next month base forward forecast contempl underli
fundament implic healthcar reform dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst expect greater potenti multipl expans dcf
valuat point significantli upsid peer current trade level free cash flow yield ratio also inform potenti multipl
expans except low ratio and/or high free cash flow yield point potenti greater multipl expans base price-to-earnings multipl
appli ep guidanc rate ci outperform price target
risk valuat non-profit bcb plan insur price irrat commerci market rapidli acceler medic cost trend medic cost
trend come higher anticip potenti econom downturn provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz econom downturn risk declin invest yield invest impair state-bas actuari rate review
limit sound price underwrit caus substanti underwrit margin compress longer term state-bas insur exchang
advers select reduc sustain earn power employ dump employe insur exchang signific margin
compress potenti downsid membership top line also present long-term risk polit shock lead singl payer compani specif risk
signific declin equiti market could result increas fund compani pension oblig polit legal oper regulatori econom
risk foreign oper
valuat cmta price target cmta deriv price target use discount cash flow dcf analysi incorpor
two indic palovaroten fop mo although intrigu potenti develop palovaroten indic dri
eye believ program preclin program earli justifi incorpor model awar palovaroten first-to-market
therapi fop mo compel safeti data promis efficaci data observ vitro mous model low power fop trial
howev promis clinic data yet observ palovaroten mo fop model estim palovaroten peak penetr us
eu translat global peak sale earlier stage mo program estim peak
penetr us eu respect translat peak sale probabl success po fop us eu
mo us eu reflect view base upon data gener date pre-commerci stage compani appli discount rate
risk valuat pre-commerci stage compani risk valuat includ clinic trial outcom delay clinic develop regulatori risk
prior approv reimburs risk post-approv awar palovaroten first-to-market therapi fop mo preced
success program thu may unforeseen challeng approv current model financi perspect clinic develop requir
signific invest could necessit dilut financ road
comput program system inc
valuat share current trade non-gaap ep histor trade mp mp
qsii mp trade discount histor ntm price-to-earnings multipl although histor price-to-earnings multipl base ep
report non-gaap basi price target base ep believ still trade discount
compani histor price-to-earnings multipl given concern face headwind due slowdown meaning use demand declin system sale
solid product attract price point down-market believ demand meaning use relat emr slow concern
manag abil predict annual earn believ invest back softwar occur addit believ
expect increas given variou concern continu rate share market perform
risk valuat new greenfield opportun could limit risk market perform rate would number new opportun limit
given small hospit want undergo quot rip replac quot process offer fairli high-qual solut smaller facil
may alreadi system place number new instal seem taper recent may suggest major sale
come compani exist base competit within healthcar space intens primari competitor includ meditech hm
compani compet directli small mid-siz hospit market secondari competitor includ mp quadram
mp siemen compani typic sell product larger hospit sometim compet directli given
arra smaller hospit may seek busi healthcar firm typic servic larger facil lumpi quarterli result could caus
errat stock behavior sale cycl typic month sale cycl instal process system time-consum
complex may difficult manag accur forecast quarter revenu earn consist basi certain project may get
push one quarter next result earn volatil unpredict share price perform govern regul could pressur oper
perform may new regul custom either limit increas much will pay new system product
develop could lag larger far focus competitor homegrown product develop engin team alabama
compani abil keep pace industri competit may difficult new product introduc compani competitor effect
respond chang industri need may unfavor impact financi result
valuat current trade in-lin peer group forward ev/ebitda vs group premium
price-to-earnings vs group discount ev/sal vs group argu histor turnaround situat
-- -where long-term revenu ep power potenti underst -- -an in-lin possibl even higher-than-grp average multipl
justifi especi ev/ebitda price-to-earnings basi pt base ev/ebitda appli ebitda peer group
includ med-tech compani either compet similar end market similar type stock characterist exac
snn demonstr abil consist execut beat consensu acceler organ
sale growth faster project deliv commensur oper ep upsid process believ could room multipl
eventu trade premium group ev/ebitda basi primari valuat metric howev without convict upsid potenti
out-year number troubl argu ev/ebitda multipl premium point time
risk valuat multipl expans margin expans prospect heavili depend abil acceler sale growth margin
expans stori heavili depend sale growth acceler thu initi take longer expect end market begin slow
unabl drive better perform exist portfolio could caus revenue/ebitda forecast risk convers faster
expect sale growth acceler model could lead higher rev/fast profit think cnmd turnaround could take longer
forecast requir heavi lift expect abil jump-start sale growth could involv reassess exist
busi divestitur could lead near-term disrupt model put forecast risk execut new product launch may
success past fit start new product launch includ delay redesign new product launch edg perform
poorli could neg impact percept customers/investor compani turn corner capit equip market cyclic
exposur mostli smaller ticket item rather multi-million dollar equip said ebb flow capit purchas could
nevertheless affect compani hospit administr re-priorit resourc alloc away product could neg impact
sale growth pagebreakm dilut could neg impact margin expect small tuck-in absorb compani oper
structur limit impact possibl manag may pursu larger deal pursuit long-term object could neg affect
margin near term similarli groom portfolio divest asset could also neg impact near-term sale growth
profit
valuat price target deriv price target use discount cash flow dcf analysi incorpor
two indic seladelpar pbc nash although also intrigu potenti develop primari scleros cholang psc
signific unmet medic need cogniz grow competit pbc ocaliva mp etrasimod op
second-lin set therefor alloc market share among agent estim seladelpar peak penetr us eu
translat global peak sale earlier stage nash program estim peak penetr us eu
respect translat peak sale probabl success po pbc us eu nash us eu
reflect view base upon data gener thu far current assign valu arhalofen program gout licens kowa
pharmaceut final pre-commerci stage compani appli discount rate termin growth rate
risk valuat pre-commerci stage compani risk valuat includ clinic trial outcom delay clinic develop regulatori risk
prior approv reimburs risk post-approv also sinc ppar/ remain least understood three ppar unforeseen complic
risk may emerg financi perspect clinic develop requir signific invest could necessit dilut financ road
valuat dbvt deriv price target dbvt share month base dcf analysi discount rate termin growth
rate assum probabl success viaskin peanut viaskin milk respect current model peak risk-adjust
revenu across viaskin peanut milk product
risk valuat risk includ disappoint clinic data regulatori setback potenti dilut financ commerci shortfal sinc dbvt
product candid still clinic trial aforement setback could impact stock significantli
valuat derm price target derm price target base dcf valuat assum discount rate probability-
adjust sale profit appli termin growth rate valuat assum late-stag asset
probabl success lebrikizumab probabl clinic success pt fully-dilut basi includ full exercis derm
convert well option
risk valuat invest derm involv pool differ risk includ technic regulatori commerci risk three fundament
differ pipelin product signific derm overal valuat opinion clinic success acn import commerci
execut associ launch underdevelop hyperhidrosi market also clinic competit risk lebrikizumab opportun
valuat price target base revenu multipl risk-adjust sale discount back multipl
middl rang use coverag univers akao aqxp balanc orphan natur offer regulatori
exclus potenti higher margin direct competit repres headwind earlier stage program also preclin
behind dcr-phxc well potenti partnership repres upsid price target discount rate consist employ earlier
development stage biotech
risk valuat face signific clinic regulatori risk sinc product candid current develop specif also
face clinic develop risk sinc none new product test human compani develop first-in-class rnai-bas drug
novel mechan addit product candid address new non-valid target similar mani development stage biopharma compani
also face manufactur competit commerci regulatori safeti risk well risk intellectu properti current involv
legal disput repres invest risk addit face financ risk dilut sharehold sinc believ compani
profit forese futur
valuat dova price target dova base dcf methodolog cash flow termin valu
forecast avatrombopag sale thrombocytopenia associ chronic liver diseas cld prior elect procedur indic assign
probability-of-success world-wide revenu stream assum discount rate line cost equiti beta relev singl
product small cap biotech peer aldr myov rarx addit factor dova cash balanc valuat
risk valuat dova singl product entiti back-up option risk view outlook valuat dova includ regulatori
reject approv avatrombopag compani sole drug approv also risk physician prescrib avatrombopag volum
match sale forecast commerci risk includ risk market entri gener nplate promacta post patent expiri though
label compet directli avatrombopag potenti launch lusutrombopag thrombocytopenia patient chronic liver diseas
undergo elect surgeri risk inher small compani includ dilut risk whereupon dova may need rais addit capit fund commerci
oper expand develop commerci shortfal risk compani lack infrastructur experi bring drug market lead
revenu realiz lower forecast
valuat edg deriv per share valu edg use blend dcf revenu multipl analys use discount rate
termin growth rate consist assumpt rel hand compani univers aldr akao meanwhil revenu
multipl middl rang use coverag reflect solid ip runway includ issuanc composit matter sale
program via intracistern deliveri earlier product current incorpor model
risk valuat risk includ disappoint clinic data regulatori setback potenti dilut financ commerci shortfal sinc edg
product candid still clinic trial aforement setback could impact stock significantli
compani
valuat dcf price target forecast sale profit use larg pharmaceut compani discount rate
termin growth rate
risk valuat risk forecast includ hindranc growth diabet oncolog anim health busi greater-than-expect clinic
setback inabl reduc cost structur critic valuat assumpt failur signific number late-stag pipelin product
could neg impact revenu assumpt final sustain dividend current level remain critic import
valuat elgx base valuat elgx group small-cap med-tech compani expect grow sale averag growth rate
ktwo -- -v elgx estimate growth growth averag ev/sal multipl
group sale appli discount group forward multipl account execut risk well chanc elgx may
abl drive market growth nellix push success pt base ev/sal multipl
turn discount group multipl elgx sale forecast use cash posit debt
risk valuat invest risksregulatori risknellix repres key growth driver elgx compani secur fda approv
nellix approv delay year forecast could risk think afx/ov could recaptur part unreal nellix revenu case anoth
delay commerci nellix us repres largest sale growth driver compani possibl addit delay nellix could
drive surgeon use elgx devic trial manufactur product risk limit portfolio breadth beyond aaaelgx play sole aaa
space compani abil servic institut look consolid purchas across cardiolog servic line limit
hospit administr decid consolid purchas larger organ elgx abil get shelf exist
account penetr new account could limit elgx potenti acquisit target upsid risk price nellix opportun
larger anticip manag demonstr double-digit revenu growth ramp profit think elgx could repres
attract asset potenti acquir think acquir appetit differenti small cap med-tech growth asset nellix appear fit
bill sentiment around name begin contempl takeout valuat could sourc upward pressur vs price target
valuat valuat base dcf methodolog discount probabl success tazemetostat
epithelioid sarcoma mutant nhl indic tazemetostat mutant nhl indic believ discount rate
appropri use probability-weight sale product includ estim cash end
risk valuat safeti efficaci tazemetostat yet well establish due earli stage develop competit
gsk compani focus target could neg impact revenu competit agent hematolog malign could
limit revenu product commerci uptak may limit reimburs access dose concern tazemetostat
valuat price target base discount cash flow sum-of-part analysi use wacc discount rate well
termin growth rate appli cash flow post anticip product patent expir
risk valuat risk includ abil continu grow product sale also face clinic regulatori risk sinc main valu driver
current multipl on-going clinic trial regulatori review like mani biopharma compani also face manufactur competit
commerci regulatori safeti risk well risk intellectu properti
valuat risk-adjust valuat valuat deriv discount multipl sales-bas analysi
incorpor probability-adjust sale probability-adjust sale protmun probability-adjust sale ipsc
platform calcul mean product revenu forecast appli multipl discount back use wacc
discount rate similar emerg early-stag platform compani coverag arql iph fp
risk valuat face commerci competit well regulatori risk cell-bas product candid platform like mani
development compani also face manufactur safeti risk well risk intellectu properti risk manag
execut specif risk relat predominantli earli develop stage compani sinc limit clinic data gener date
product candid
valuat price target base dcf sum-of-the-part methodolog includ probability-weight
roxadustat royalti mileston payment astella eu japan azn us row roxadustat profit-shar azn mp china
territori assum probabl success dialysis-depend chronic kidney diseas ckd indic probabl success
non-dialysi depend ckd indic current model probabl success po pamrevlumab ipf pancreat cancer
assum discount rate believ appropri given probability-weight sale includ termin growth rate beyond
risk valuat clinic risk includ abil roxadustat show statist signific improv clinic relev trend toward improv
cardiovascular cv outcom versu erythropoietin-stimul agent esa phase dialysi trial placebo phase non-dialysi
trial unknown safeti issu associ phd inhibit hif stabil clinic regulatori risk associ bring new class market
variou territori particularli china uncertain size potenti anemia market particularli outsid dialysi set unknown reimburs landscap
us regard inclus roxadustat prospect payment aka bundl competit hif-ph inhibitor anemia
md pamrevlumab safeti signal inferior result phase ipf trial compar phase ii trial manufactur develop setback delay
pamrevlumab compar launch date
valuat pt base probability-adjust multipl sale analysi use discount rate attribut
cabiralizumab assum probabl success assum probabl success platform preclin pipelin
rest net cash use multipl product sale multipl royalti
risk valuat face signific clinic regulatori risk sinc product candid current earli stage preclin clinic
develop like mani development stage biopharma compani also face manufactur competit commerci regulatori safeti risk
well risk intellectu properti also face financ risk dilut current sharehold sinc believ compani cash flow-
posit forese futur
valuat gsk forecast ep compound-annual-growth-rate reflect gener competit new product launch base pro forma dcf
includ impact nvs-gsk swap forecast sale profit believ gsk could trade next
risk valuat risk gsk includ earlier introduct launch advair gener slow breo anoro launch dcf-base
price target assum ab-rat respiratori devic introduc end follow fda guidanc medacorp regulatori specialist place
high probabl anda approv respiratori devic
valuat pt assum trade wider ev/ebitda premium peer exac snn
current average forward ev/ebitda trade premium peer group would
impli ev/ebitda higher current level base ebitda would yield believ sustain best-in-class
ebitda margin deliv acceler top-lin revenue growth hsd low-dd forward ev/ebitda multipl continu expand
ebitda current premium widen vs peer premium current boast almost higher
margin profil vs peer group averag believ top-lin growth hsd/low dd rang sustain next month vs peer group average
msd/hsd last two revenue growth acceler period stock saw ev/ebitda multipl reach average
premium vs peer peak revenue growth appli premium group multipl would impli
risk valuat risks/uncertainti includ spine market pricing/volum pressur see bigger than-expect slowdowneith due
increas insur pushback weak economyand/or broader industri price pressur spread minim invas surgeri mi spine product offer
could put pressur sale growth opportun compani robot trauma product pipelin could take longer expect gain
traction gener revenu new rep hire recruit initi take longer-than expect drive higher rep product and/or improv
compani core us spine busi could put growth acceler trajectori risk caus improv y/i organ growth take longer-than-
project materi integr continu gener momentum struggling/slowli improv busi could put
ou sale growth acceler estim risk higher level reinvest alreadi contempl model requir
sustain top-lin could caus ebitda margin fall level could limit ev/ebitda multipl expans
prospect
valuat gwph estim risk-adjust per-adr gwph valu month attribut valu epidiolex sativex eu current net
cash balanc use dcf analysi believ gwph may launch epidiolex independ global basi use discount rate consist
model compani de-risk phase program probability-weight epidiolex revenu project
dravet lg includ off-label sale model consist use clobazam prescrib wide sole approv
lg util termin growth rate could conserv gwph pipelin product schizophrenia autism brain cancer
encephalopathi gener posit de-risk data gwph abl improv patent posit epidiolex gwph abl gener cannabinoid
therapeut proprietari discoveri platform
risk valuat risk includ potenti disappoint clinic data regulatori setback commerci shortfal competit potenti
dilut equiti rais epidiolex yet obtain regulatori approv jurisdict guarante favor phase data lead
approv aforement setback could impact stock significantli
valuat primari valuat methodolog base rel ev/ebitda rel ev/ebitda track function
compani histori hospit group averag assess potenti ev/ebitda expans next month base forward
forecast contempl underli fundament implic healthcar reform base rate outperform price target
base ev/ebitda ebitda view
risk valuat downsid risk valuat includ possibl delay medicaid expans current non-expans state headlin risk
gop effort repeal downsid risk leverag legisl regul cut govern commerci payer reimburs
valuat deriv pt use dcf project cash flow patent expir use wacc
termin valu
risk valuat sustol growth trajectori impact reimburs hurdl ph data robust expect addit financ
need
valuat imdz price target imdz base blend dcf analysi revenu multipl analysi assign valu
probability-weight sale synovi sarcoma probabl success also assign valu probability-weight sale follicular
lymphoma probabl success potenti address indic repres upsid estim use discount
rate termin growth rate
risk valuat imdz pipelin program face clinic regulatori develop risk well manufactur commerci intellectu properti
risk imdz also face execut risk financi risk also imdz may addit financ need turn cash flow posit
valuat price target share month base discount cash flow dcf valuat analysi valuat attribut
mirvetuximab soravtansin base probability-of-success weight forecast potenti probability-weight royalti partner
expect cash year use discount rate similar late clinic develop stage compani coverag
arri juno termin growth rate
risk valuat risk price target includ uncertainti size commerci potenti mirvetuximab clinic regulatori reimburs
commerci risk proprietari partner pipelin well financi risk current cash-flow neg may requir addl
financ within next month
valuat ifrx ifrx leverag proprietari mab first-in-class therapi patient moderate-sever hidraden suppurativa
hs rare autoimmun diseas skin caus excess activ project probabl success po us eu hs
due differenti preclin data togeth success complet safeti trial demonstr respons rate refractori
moderate-sever hs patient balanc uncertainti due limit patient exposur date current model assign credit
program anca-associ vascul aav yet clinic believ inflarx share best valu via dcf analysi use
discount rate termin growth rate convert impli market cap eur usd use fx averag yield pt
risk valuat pre-commerci stage compani risk valuat includ clinic trial outcom delay clinic develop regulatori risk
prior approv reimburs risk post-approv also sinc first-in-class therapi unforeseen complic risk may emerg
financi perspect clinic develop requir signific invest could necessit dilut financ road
valuat price target appli ev/sal multipl sale estim assum stabl multipl
current share trade today estim ev/sal multipl small-cap med-tech univers
nxtm broadli believ repres uniqu asset within small-cap med-tech top-tier
growth profil profit togeth warrant premium
risk valuat risk share includ account issu possibl greater reimburs cut current model loss
increment competit bid contract exclud compani access new patient potenti competitor replic implement
compani dtc strategi inabl build awar drive increas penetr poc oxygen therapi market
valuat estim risk-adjust per share price target month use wacc discount rate sinc risk
involv drug develop regulatori approv intellectu properti litig alreadi handicap probability-weight revenu
longer term assum termin growth rate
risk valuat risk includ potenti disappoint clinic data regulatori setback failur obtain intellectu properti protect abroad
commerci shortfal sinc present unprofit one commerci product possibl aforement setback may impact
stock significantli
valuat estim fair valu month share valuat deriv dcf analysi appli discount rate
consist pre-clin stage compani coverag dbvt pti qure termin growth rate support
optim technolog potenti long term follow consumm mp -kite deal oct appli
minor premium valuat given compani car-t hematopoiet stem cell partnership nv mp
risk valuat like pre-clin stage compani invest risk includ disappoint clinic data regulatori denial delay unanticip
delay drug develop termin establish partnership and/or collabor also add neg sentiment among investor import risk
howev pertain patent crispr/ technolog product-specif ip protect compani revenu stream long term
valuat price target base discount cash flow dcf analysi assum discount rate
termin growth rate estim peak penetr oca pbc ursodeoxychol acid urso non-respond us compris
pbc popul price target assum probabl acceler approv oca nash probabl approv post-outcom
benefit
risk valuat risk includ potenti disappoint clinic data regulatori setback commerci shortfal possibl setback may
impact stock significantli
valuat pt base dcf assum discount rate long-term free cash flow growth rate
gener posit free cash flow nopat a-capex-work capit increas margin rapidli thereaft price target reflect
ev/sal ev/sal would reflect premium comp group high growth med-tech peer
entl trade average ev/sal given belief abl acceler
revenu growth rang above-group-avg gm profil think premium valuat justifi especi
pipelin approv standpoint essenti de-risk pt also support sotp analysi assign separ valu
or/surg busi in-offic pipelin arriv valu base surgic busi assum multipl appli
or/surg revenue account assum cash posit pipelin valu start in-offic revenue
assumpt discount back appli ev/sal multipl get us valuat take two togeth
get us
risk valuat estim could risk exist product propel propel contour sale take longer expect materi
pipelin product sinuva take longer receiv approv adopt compani product progress level model
reimburs reduct went effect jan begin greater impact util privat insur follow lead reduc
payment level sinu procedur compani ultim receiv broader reimburs addit favor coverag decis hinder
greater adopt secur reimburs sinuva product competitor could pursue/ develop solut compet
product
valuat deriv price target share base blend revenu multipl dcf analysi use
discount rate consist model stock nda fileabl asset gwph previous recent approv
model peak us sale schizophrenia bipolar dementia behavior disturb revenu
respect probability-weight project near term schizophrenia model includ scenario analysi
probabl approv outcom
risk valuat invest fundament high-risk high-reward invest opinion may face signific clinic regulatori
commerci risk pipelin product yet gener long-term safeti studi lumateperon requir fda approv also
competit risk antipsychot therapi final investor face risk dilut financ
valuat ivti pt appli ev/sal multipl sale assum ivti see multipl expand
current level trade close line group small-cap market cap med-tech compani trade ev/sal
ev/sal current ev/sal basi ivti trade discount sale peer group includ
cybx entl elgx exac ktwo nxtm think discount warrant
degre order account execut risk associ earlier-stag sale compani high rate cash burn balanc sheet risk
compani admittedli choppi execut outlook reset recent qtr howev consist quarterli execut unfold above-avg revenue growth
perform think compani could see multipl move toward broader group given expect ivti deliv top-lin growth
also still consid ivti risk-reward heavili skew upsid believ ivti repres potenti target
portfolio pipelin could fit nice virtual compani call point multipl call point across gen surgeri orthoped gyn
risk valuat penetr new hospit account could take longer expect sell process heavili depend recruit
surgeon champion technolog also gener support hospit administr level -- -i get new product approv committe
lengthi involv process invuiti unabl convinc hospit administr surgeon and/or c-suit execut increment
benefit associ waveguid worth increment cost/procedur could act impedi invuiti new account open and/or
drive deeper penetr exist account across multipl surgeri specialti potenti resist custom integr waveguid technolog
beyond initi procedur adopt compani may success get devic trialed/us one four main beachhead procedur
guarante rep abl success cross-sel break addit procedur area across cover institut could limit compani
depth penetr instal base result lower util per account model ultim potenti put sales/profit
forecast risk sale expans sell execut compani unabl hire rep quickli project rep take longer
anticip come product curv could limit compani abil open new account and/or penetr deepli exist one
time manner potenti repres downsid risk estim pushback price perceiv valu proposit invuiti mani abl preserv
price potenti put revenu forecast risk custom push back product valu proposit greater extent
contempl competit devic -- -current market road -- -offer enhanc illumination/visu come view
offer better valu lower price could also put invuiti price strategi thu revenu potenti risk compani produc
strong enough clinic cost-benefit evid justifi increment per procedur cost associ waveguid technolog
valuat juno price target juno share base dcf analysi probability-weight sale juno car-t product
hematolog indic salvag set use discount rate reflect celg estim wacc termin growth rate
risk valuat juno may receiv higher acquisit bid think unlikelyalthough unlik celg acquisit juno may close
valuat price target month base discount sale multipl analysi appli discount rate
probability-of-success po weight selinexor sale four relapsed/refractori singl agent hematolog cancer indic dlbcl mm well
dedifferenti liposarcoma use multipl product sale multipl royalti line compar biotech compani
arql use wacc discount rate think appropri reflect risk level earli stage compani
risk valuat earli stage biotech compani face signific clinic regulatori develop risk well commerci risk also
face execut risk financi risk estim current cash suffici fund oper vast major valuat
base selinexor compani clinic stage product candid potenti setback due possibl safeti and/or efficaci relat issu selinexor
could signific impact valuat
valuat price target base blend dcf analysi revenu multipl analysi assign valu
probability-weight us sale tipifarnib hra mutant squamou cell carcinoma head neck scchn probabl success hra mutant
solid tumor probabl success peripher cell lymphoma probabl success myelodysplast syndrom md probabl
success cmml probabl success assum royalti ex-u tipifarnib sale futur partnership earlier stage program
menin-ml inhibitor repres upsid valuat use discount rate termin growth rate
risk valuat pipelin program face clinic regulatori develop risk well commerci intellectu properti risk also
face execut risk financi risk may addit financ need turn cash flow posit
valuat price target share month base discount sale multipl analysi use discount rate
probabl success-weight margetuximab breast cancer gastroesophag cancer indic pursu
sale rest cash-per-share use multipl product sale multipl royalti line
risk valuat development pipelin agent face clinic regulatori develop risk well commerci risk also face execut risk
financi risk estim current cash suffici fund oper compani may addit financ need
turn cash flow posit
valuat trade ep estim ep estim w/ cubist dcf-base
month price target forecast sale profit larg pharma discount rate assum termin growth rate
risk valuat risk includ competit rival pipelin dpp-iv inhibitor well competit keytruda io
broadli specif lung cancer margin success develop daa hcv combin
valuat price target valuat deriv discount multipl sales-bas analysi incorpor
probability-adjust sale calcul mean product revenu appli multipl respect
discount back use wacc discount rate similar emerg early-stag platform compani coverag arql
risk valuat face commerci competit well regulatori risk product candid platform like mani
development earli commerci stage compani also face manufactur competit commerci regulatori safeti risk well
risk intellectu properti risk manag execut specif risk relat earli develop stage compani sinc limit clinic data
gener product candid date gener gener highli activ preclin tumor model result
alway translat clinic dose-limit toxic man alway predict base data preclin model
valuat estim price target share month base discount sale multipl analysi use discount
rate probabl success-weight sitravatinib sale valuat account probabl success po sitravatinib singl agent
sitravatinib combin w/ opdivo
risk valuat earli stage biotech compani face extens clinic regulatori risk well commerci risk also face
execut risk financi risk estim current cash suffici fund oper late compani may addit
financ need turn cash flow posit
valuat nbrv deriv price target nbrv use blend dcf analysi multipl risk-adjust sale use
discount rate termin growth rate discount rate rang compani univers stage op
sale multipl consist gener biotech multipl via discount sale reflect somewhat lower margin slower ramp
infecti diseas product line model anti-infect peer cdtx op assum probability-of-success balanc
posit data along variou uncertainti discuss risk valuat section
risk valuat risk nbrv valuat includ dilut risk project addit equiti rais data posit
howev studi examin quot oral-onli quot lefamulin regimen never studi fda/ema risk nbrv
spa risk fda chang regulatori requir done anti-infect past risk commerci shortfal due
reimburs challeng lack physician uptak believ could impact stock significantli
valuat nvcn next month believ nvcn share trade arriv price target use discount cash flow dcf
analysi take averag valuat base rang royalti rate dcf use discount rate probability-
weight believ dcf appropri consid neovasc expect sale inflect point tiara potenti ce mark approv launch earli
potenti approv launch acknowledg small-cap med-tech compani valu base compar compani
ev/sal multipl believ dcf best captur total address market opportun neovasc tiara tmvr market estim
risk valuat risk neovasc rate valuat includ possibl tiara and/or reduc approv us and/or europ
commerci ramp tiara and/or reduc fail meet expect challeng fda approv pathway tiara and/or reduc fairli robust
competit landscap mr replac pipelin on-going trademark potenti patent litig potenti reimburs risk failur
obtain suffici reimburs tiara and/or reduc secur approv
valuat dcf-base price target use discount rate termin growth rate see assumpt
rel consist model biotechnolog compani coverag de-risk phase data and/or partner product
gwph model risk-adjust market opportun valbenazin ingrezza td use us row
probability-of-success gross us elagolix sale across endometriosi uf use probabilities-of success gross
ingrezza sale tourett risk-adjust probability-of-success assum strong revenu growth valbenazin elagolix
respect patent expiri without hatch waxman occur
risk valuat risk invest includ potenti disappoint clinic data valbenazin elagolix regulatori setbacksth
potenti longer fund elagolix develop commercializationcommerci challeng valbenazin need compet teva
strong market presenceth potenti dilut financ believ could impact stock significantli
valuat nite price target nite deriv price target use discount cash flow dcf analysi incorpor
lead asset choroideremia/chm nsr-rpgr x-link retin pigmentosa/xlrp current estim
peak sale chm xlrp respect account posit data publish literatur lancet nejm assign
probabl success po us eu po earlier stage nsr-rpgr us eu believ develop gene
therapi candid rare diseas target select coe trial commerci could incur rel lower oper expens compar
preval indic requir larger sale forc consist pre-commerci stage compani coverag includ auph dbvt
appli discount rate termin growth rate
risk valuat pre-commerci stage compani risk valuat includ clinic trial outcom delay clinic develop regulatori risk
prior approv reimburs risk post-approv also limit real-world experi gene therapi medicin although luxturna
address differ diseas target differ gene neg safeti concern disappoint uptak commerci set could caus neg
repercuss nite dilut financ also risk compani achiev profit
valuat nv nv current trade ep ep roughli line global pharmaceut
group averag azn gsk novo nv sni price target base blend dcf-base
valuat sotp-bas valuat dcf valuat base group wacc assum termin growth consist
innov compani coverag univers sotp analysi base ev/ebit vs ebit compound-annual-growth-rate regress quot pure play quot
larg pharma biotech compani innov medicin ev/ multipl sandoz alcon consum joint ventur gsk mp
valuat rhhbi nr stake valuat outlook includ prospect improv oper margin prospect acceler pharma
margin post assum growth sever new pipelin driver
risk valuat risk nv valuat includ potenti declin sale growth gilenya tasigna chronic myeloid leukemia cml
increas competit new agent gleevec gener well commerci prospect afinitor hormon resist breast cancer kidney cancer
valuat nvo forecast ep compound-annual-growth-rate reflect robust novel product launch partial off-set sustain price pressur
potenti biosimilar competit base dcf valuat assum discount rate termin growth rate sale profit
believ nvo trade near next month
risk valuat risk nvo valuat includ worse-than-expect pricing/market share eros biosimilar failur key pipelin product
semaglutid stronger-than-expect foreign exchang headwind rapid slowdown emerg market growth prospect
valuat obsv deriv price target obsv share base blend revenu multipl dcf analysi model also use
discount rate termin growth rate see rel consist compani phase akao revenu
multipl low end rang use compani coverag univers account slightli lower margin obsv due
royalti oblig also risk elagolix generic could neg impact net price gnrh antagonist class use odd
success conserv probabl nolasiban
risk valuat invest obsv fundament high-risk high-reward invest opinion obsv may face signific clinic regulatori
commerci risk pipelin product also signific competit risk therapi women health space includ
abbv/nbix myov final obsv investor face risk dilut financ model equiti rais
valuat ome deriv price target ome share valu ome io agent target gitr tigit use discount
probability-adjust sale multipl valuat method remaind estim cash
risk valuat develop risk pipelin asset still early-stag clinic preclin develop could fail develop
stage ome agent first-in-class improv upsid upon success development risk may higher lead drug advanc
control studi therapi target cancer stem cell design may affect small sub-popul tumor cell observ anti-tumor signal
earli clinic develop may challeng demonstr clinic efficaci may requir random studi longer follow-up financ risk
ome guid suffici cash fund oper risk possibl partner celg could decid opt-in
ome product candid
valuat deriv price target share base blend revenu multipl dcf analysi former use
multipl risk-adjust sale latter use discount rate termin growth rate see consist
rang use model late stage compani posit phase data infecti diseas akao sale multipl consist
recent take-out multipl includ conting valu right assum probability-of-approv absssi
cabp base posit phase data skin posit phase data pneumonia drug met key efficaci endpoint believ
omadacyclin clinic potenti uti sinus could repres upsid long term current model probability-of-success
former includ sale latter model
risk valuat risk valuat includ potenti disappoint clinic data regulatori risk commerci shortfal given
omadacyclin compris vast major valuat efficaci safeti regulatori commerci setback program may impact stock
significantli investor also face potenti dilut risk model addit equiti rais
valuat trade low end leerink major pharmaceut univers azn gsk nv nvo sni may
appeal value-bas investor base high oper cash flow yield dividend yield opportun organ growth appear
rel limit discount cash flow analysi valu sale profit assum discount rate
risk valuat risk invest thesi valuat includ exclus loss therapeut substitut slow key driver trend large-scal
put dividend risk product commerci risk face in-class competit notabl fda breakthrough-design product
palbociclib ibranc metastat breast cancer
valuat pt base discount cash flow dcf analysi assum discount rate termin growth
rate estim probabl launch assum peak penetr biolog refractori uc patient peak penetr
first-lin treatment uc patient lead ww risk-adjust peak revenu also current model probability-weight peak revenu
preclin asset includ
risk valuat includ potenti disappoint clinic data regulatori setback commerci shortfal amend partnership
janssen/jnj asset sinc protagonist present one asset clinic trial possibl setback may impact stock
significantli
valuat price target valuat deriv dcf-base analysi incorpor forecast neratinib nerlynx
sale adjuv metastat breast cancer treatment use wacc discount rate termin growth rate post patent expir
expect compar similar compani coverag
risk valuat face commerci competit well regulatori risk neratinib nerlynx like mani development earli
commerci stage compani also face manufactur competit commerci regulatori safeti risk well risk intellectu
properti risk manag execut
valuat qsii qualiti system inc share current trade adjust ep slightli hcit group qsii
averag ep compani histor ep averag ntm ep estim next month
share trade lower non-gaap ep cautiou qsii appear though
piec turnaround plan take hold attrit sale forc prevent qsii achiev book growth goal entrada
eagledream deal posit higher convict qsii abil improv client satisfact howev believ compani new
product take time gain traction expect higher remain earn headwind believ stock benefit take-out
specul convict pipelin start stabil appear manag take right step restructur compani
increas oper leverag drive cross-sel effort encourag turnaround effort manag put forth believ
signific work requir fulli transform busi cloud-bas enterpris result maintain mp rate
risk valuat sever vendor begun undercut qualiti system premium vendor price effort buy market share
believ qsii resist price pressur point could forc either conced price share face intens competit addit qsii
revenu earn may fluctuat significantli quarter quarter given delay purchas relat arra lack clariti around certain
definit within legisl pressur sharehold previou board member hussein repres distract uncertainti remain around
futur board composit believ share could neg impact hussein attempt rejoin board begin dump share final
lumpi earn revenu may caus stock price volatil either direct
valuat rate share outperform pt leverag proprietari target therapi bard omav
develop novel therapeut patient rare life-threaten diseas caus dysregul metabol mitochondri function program
seek either improv upon current standard care ctd-pah becom first-to-market therapi diseas approv therapi exist
alport syndrom fa mitochondri myopathi conserv project probabl success po bard ctd-pah due advanc
follow rel small phase residu uncertainti surround mechan action appropri patient
popul howev believ catalyst trial highli power alport syndrom ascrib po bard base highli encourag
cardin data extens clinic histori increas estim glomerular filtrat rate egfr singl endpoint approv ascrib po
omav fa due earlier stage develop rel intract diseas model assign credit program potenti
revenu gener collabor pipelin multipl innov product routin seen clinic stage biotechnolog compani
result develop regulatori market reimburs uncertainti believ share best valu via dcf analysi use discount rate
termin growth rate yield pt
risk valuat pre-commerci stage compani risk valuat includ clinic trial outcom delay clinic develop regulatori risk
prior approv reimburs risk post-approv also sinc bardoxolon omaveloxon first-in-class therapi unforeseen complic
risk may emerg financi perspect clinic develop requir signific invest could necessit dilut financ road
valuat rgl rate rgl share op pt rgl leverag proprietari anti-mir oligonucleotid platform develop novel therapeut
patient rare life threaten genet kidney diseas regulu seek first-to-market therapi alport syndrom via lead program
conserv project probabl success po alport syndrom due promis preclin data success complet
safeti trial off-set uncertainti stem absenc histor evid regard efficaci human suffer chronic
kidney diseas ckd alport syndrom model incorpor scenario analysi evalu chang potenti revenu base
sanofi decis opt-in -out determin sinc opt-in scenario beyond month project pt model
scenario sanofi opt-in rgl develop market us sanofi opt-in valuat could rise addit
model assign minim credit adpkd program po reflect current ph clinic statu program pend poc
data demonstr safeti efficaci nake oligonucleotid rectifi diseas kidney regulu pipelin contain first-in-human therapi
routin seen clinic stage biotechnolog compani subject clinic regulatori market reimburs uncertainti believ regulu
share best valu via dcf analysi use discount rate termin growth rate yield pt
risk valuat pre-commerci stage compani risk valuat includ clinic trial outcom delay clinic develop regulatori risk
prior approv reimburs risk post-approv also sinc first-in-class therapi unforeseen complic risk may emerg
financi perspect clinic develop requir signific invest could necessit dilut financ road
valuat believ price target reflect strength base busi inclus thiola chenod cholbam potenti
valu pipelin asset appear under-valued current market valuat estim gross market opportun
sparsentan fosmetpantoten formerli probabl launch sparsentan fosmetpantoten liquid
udca ursodeoxychol acid phenylketonuria/pku yet reflect model valuat pend visibl
market opportun develop pathway respect dcf analysi assum discount rate termin growth rate indic
price target month
risk valuat risk valuat includ potenti commerci clinic regulatori disappoint across compani exist product includ
thiola cholbam chenod develop pipelin includ sparsentan fosmetpantoten formerli contribut materi way
valuat
valuat estim price target month use dcf analysi dcf valuat employ discount rate
termin growth rate higher rang biotech compani similar nbrv reflect fact
develop drug high risk neurosci indic termin growth rate mostli consist across coverag base case assum
probability-weight tremor sale use probability-of-success
probabl ppd/tremor final includ odd success major depress disord though high risk address
largest potenti market opportun ww risk-adjust sale follow-on program n-methyl-d-aspart nmda modul
parkinson diseas current captur model
risk valuat risk valuat includ disappoint clinic data regulatori setback potenti dilut financ commerci shortfal
two product clinic yet gener posit phase data expect unprofit near term
occurr could impact stock significantli
valuat sni san fp trade ep repres discount leerink partner large-cap
pharmaceut coverag univers san fp rel price-to-earnings discount leerink pharmaceut coverag sni azn nvo
nv gsk larg reflect risk base busi see upsid opportun late stage pipelin opportun well
contribut addit forecast reflect potenti accret capit alloc opportun major share repurchas dcf
analysi forecast sale free cash flow appli termin growth rate wacc result price target san fp
share month pro forma analysi announc bivv acquisit would bring dcf valuat month base
risk valuat risk sni includ weak emerg market growth disappoint growth new genzym includ ms drug aubagio
lemtrada materi delay advanc alirocumab antibodi high cholesterol dupilumab moder sever atop dermat and/or
sever atop asthma acquisit bioverativ close close time manner
valuat estim risk-adjust per share fair valu month current model peak probability-weight
eteplirsen/exondi ww revenu addit revenu deriv follow-on candid
use sum-of-part discount cash flow dcf valuat methodolog attribut eteplirsen/exondi srp-
rest net cash use wacc discount rate sinc announc eteplirsen exondi fda approv assum
us eu probabl eteplirsen/exondi approv commerci success longer term assum termin growth rate
may warrant adjust pend fda decis confirmatori studi sinc eteplirsen stand valid mechan action subsequ exon-
skipper assign probabl success po us/eu respect po potenti
launch respect
risk valuat risk includ potenti disappoint clinic data regulatori setback commerci shortfal sinc present one
product later-stag clinic trial pipelin util chemic formul possibl setback may impact stock significantli
valuat scph discount cash flow use discount rate arriv price target revers dcf indic stock
current level reflect sale reach roughli vs estim enterpris valu vs lp
risk valuat risk valuat includ fda approv delay furoscix payer coverag may take longer anticip pipelin failure/
delay
valuat price target base-cas valuat deriv dcf-base analysi probability-adjust sale
adcetri enfortumab vedotin tisotumab vedotin earli stage pipelin dcf analysi use wacc consist
commerci stage compani coverag termin growth rate
risk valuat risk valuat seattl genet includ uncertainti size commerci potenti adcetri clinic risk addit
indic still-limit safeti experi remain regulatori execut risk adcetri pipelin candid
valuat next month believ share trade price target appli ev/sal multipl
sale estim sale estim appropri metric measur eversens launch trajectori view
current share trade estim basic line small-cap med-tech coverag univers
 current trade sale estim believ premium warrant senseon near-to-medium term sale growth profil top-tier
hyper-growth small-cap med-tech elgx nxtm spnc averag mid-teen project sale growth well
sale growth compound-annual-growth-rate project time-frame share benefit number posit catalyst
next month includ eversens xl uk launch eversens launch expect
risk valuat risk share includ difficulti shift physician adopt away current tradit cgm therapi increas
competit counter-detail failur build success sale forc train physician drive adopt failur advanc pipelin includ
sensor expand indic pediatr
valuat deriv per share valu use discount rate termin growth rate repres market
capit within indic model assum probabl success po voretigen neparvovec approv
commerci leber congenit amaurosi lca type retin pigmentosa us eu respect within liver-
mediat diseas shown promis data phase studi investig hemophilia partner somewhat
cautiou phase studi investig hemophilia result current assign po respect
deriv clinic data current develop statu compar hemophilia gene therapi candid cover uniqur
valrox biomarin two program cautiou spk-chm choroideremia
diseas assign po spk-chm po reflect signific competit nightstar biomarin brineura
risk valuat risk includ disappoint clinic data regulatori setback potenti dilut financ commerci shortfal sinc
product candid clinic trial pioneer gene therapi aforement well unforeseen issu may aris durabl
shortfal higher pre-exist neutral antibodi titer higher immun respons seen small clinic trial could impact stock significantli
valuat estim per share valu share month base dcf analysi assum discount rate
termin growth rate account risk clinic regulatori drug develop probabl success estim rang
pku ucd valuat paramet reflect promis preclin data view off-set
uncertain safety/efficaci profil candid still earli stage develop given lack visibl progress
collabor develop synthet biotic ibd explicitli model royalti revenu program use altern compar market cap
valuat analysi comp analysi could valu platform view midst average peer group compani
pioneer platform earli clinic develop
risk valuat develop proprietari platform transloc metabol function variou organ gut novel
approach innov platform come high safeti efficaci risk although preclin data seem convinc platform earli stage
develop clinical/regulatori develop could disappoint unpredict issu may aris includ safeti efficaci manufactur regulatori
requir market recept unanticip complic could impact stock neg
valuat mdco estim fair valu month mdco share sum-of-the-part dcf analysi includ net cash overal use
wacc discount rate sinc risk involv drug develop regulatori approv alreadi handicap probability-
weight revenu estim pipelin asset appli termin growth rate continu assum peak vabomer revenu
mdco receiv royalti net sale melinta probability-weight peak inclisiran revenu
risk valuat risk associ clinic develop commerci activ impact mdco valuat earn power signific
invest necessari develop inclisiran trial delay dilut financ and/or failur deliv non-dilut financ plan continu weak
broader market pose risk
valuat one-year price target repres dilut market capit valuat base
probability-adjust multipl sale analysi appli multipl probability-adjust mean us fc sale row
royalti respect use wacc discount rate similar small-cap biotech stock coverag valuat base integr
three possibl scenario probability-weight scenario bear case scenario trial fail believ share would trade net
cash estim base case scenario result posit larger phase trial requir registr recurr
hgg scenario estim share could doubl per bull case scenario result posit therapi
obtain acceler fda approv base phase ii result scenario estim valuat roughli current level current price
target attribut likelihood bull case base case bear case current attribut valu potenti
indic fc view potenti sourc upsid valuat
risk valuat investor face technolog clinic risk sinc lead product candid yet evalu larg random clinic
trial like mani development stage biopharma compani also face manufactur competit commerci regulatori safeti risk well
risk intellectu properti toca also face financ risk dilut current sharehold sinc believ compani becom cash flow
posit current fund
valuat tril usd price target tril share one year base probability-adjust multipl sale analysi model sirpfc
probabl success acut myelogen leukemia aml myelodysplast syndrom md cancer appli multipl us
sale multipl eu royalti use wacc discount rate similar small-cap biotech stock coverag
sinc revenu assumpt alreadi probability-of-success weight
risk valuat investor tril face signific scientif target-rel clinic risk sinc lead product candid current earli preclin
develop like mani development stage biopharma compani tril also face manufactur competit commerci regulatori safeti risk
well risk intellectu properti tril also face financ risk dilut current sharehold sinc believ compani cash flow-
posit forese futur specif risk current valuat target risk although promis pathway yet clinic
valid target human clinic safeti and/or efficaci data exist valid pathway mechan drug target scientif risk much publicli
avail scientif work valid pathway target preclin knowledg gener one institut stanford univers introduc
potenti scientif bia risk safeti risk express healthi human tissu includ red blood cell rbc introduc potenti safeti risk and/or
risk around therapeut window molecul disappoint clinic data competitor could also neg affect tril dilut risk
addit common share tril current convert prefer share well warrant option outstand convers could
significantli dilut common sharehold valuat take potenti dilut secur account use treasuri stock method
valuat qure estim fair valu qure share one year base discount cash flow dcf analysi use wacc
discount rate similar earli stage pre-commerci small-cap biotech stock coverag termin growth valu due inabl repeat
dose gene therapi
risk valuat invest qure fundament high-risk high-reward invest opinion despit receiv first regulatori approv
gene therapi categori glybera qure still need address clinic regulatori risk subsequ candid develop
hemophilia front competit longer act factor rnai gene therapi compani could deem qure program riski broader
perspect system impact gene therapi failur new case leukemia could pose signific risk final despit strateg
initi financ risk remain expect compani cash-flow posit sever year
valuat primari valuat methodolog base rel ev/ebitda rel ev/ebitda track function
compani histori hospit group averag assess potenti ev/ebitda expans next month base forward
forecast contempl underli fundament implic healthcar reform dcf valuat leverag forward forecast wacc
termin growth rate point potenti multipl expans along sector compani specif catalyst expect greater potenti
multipl expans dcf valuat point significantli upsid peer current trade level base rate outperform
price target base ev/ebitda ebitda
risk valuat downsid risk valuat includ possibl delay medicaid expans current non-expans statesheadlin risk
gop effort repeal alter two midnight ruleacut care segment highli concentr la vega texaslow expect near-term
benefit econom tailwindsmor cut govern commerci payer reimbursementincreas uninsur admiss pardon
undocu individualsdeclin receiv collect rate
valuat vocera histor trade hcit group athn qsii ntm ev sale averag next
month expect trade ev sale reflect improv current multipl repres price target lower
reflect chang account standard likelihood posit guidanc revis anticip oper leverag confid
manag enjoy improv market better visibl extens capabl better sale momentum encourag grow
product portfolio high custom sticki effort increas channel partner sale invest stronger integr vendor also
gain momentum larg enterpris govern deal also believ manag take conserv approach guidanc
risk valuat relianc nuanc vocera current use nuanc core voic recognit softwar chang compani relationship
nuanc lead termin exist contract could result vocera incur signific cost redesign new voic recognit solut
transit new vendor current evergreen provis contract allow vocera stockpil licens exist contract termin
would give vocera abil buy time develop plan transit could also result larg up-front cost guarante new
solut would amount custom satisfact manufactur disrupt vocera manufactur facil reli
contract manufactur produc hardwar compon accessori disrupt manufactur facil contract disput could result difficulti
obtain compon devic initi product badg began transit mexico could greater
risk disrupt manufactur mexico acquisit integr risk vocera alreadi made sever small acquisit futur may acquir
addit asset vocera need fulli integr acquir solut overal product portfolio achiev strateg financi benefit integr
also expens time consum without guarante success evolv competit believ vocera hand free wireless
commun devic avail hospit believ vocera badg wide valu nurs hospit staff hand free natur voic
optim abil direct hand free competitor in-build wireless phone built compani cisco ascom polycom well
avail enterpris commun softwar voalt smartphon offer altern badg believ badg fill nich
smartphon cell phone possibl futur trend new competit could shift user differ platform devic could
advers impact vocera sale patent intellectu properti intellectu properti right remain import competit advantag vocera vocera
current patent patent applic pend approv vocera technolog system fail work expect
patent protect softwar becom compromis busi could harm intellectu properti lawsuit brought compani
could also harm oper result vocera incur cost protect intellectu properti relianc voic commun solut healthcar
market vocera deriv revenu sale voic commun solut hospit healthcar facil
compani revenu non-healthcar custom high concentr one industri vertic primarili one product compani
long-term success may reliant develop new softwar featur exist solut may challeng vocera expand new market
industri countri cost may incur add speech recognit capabl addit non-english languag lengthi sale cycl
typic take month larg health system potenti custom make decis whether buy vocera technolog servic
contribut lumpi compani report revenu earn quarter quarter addit manag disclos backlog
annual basi limit investor visibl sale prospect quarterli basi wi-fi infrastructur vocera oper wireless infrastructur
within facil vocera partner wi-fi vendor cisco proper function vocera devic reli robust wi-fi network well
maintain meet appropri standard gap wi-fi coverag within facil lead vocera badg lose recept perceiv
user issu vocera even wi-fi network fall short hospit unwil instal requir wi-fi infrastructur upgrad
exist infrastructur could function issu vocera voic commun solut may result prospect custom purchas
softwar exist custom may expand upgrad contract hc reform industri regul vocera devic softwar solut may becom
heavili regul could increas cost associ test meet requir part healthcar reform excis tax
appli medic devic begin januari anticip vocera badg fall categori classif could
increment headwind sale vocera badg commun solut compani current consid wireless badg general-purpos
commun devic subject fda regul howev badg becom integr bedsid monitor medic devic
possibl badg could also reclassifi medic devic
valuat deriv price target share use blend probability-of-success po adjust discount cash flow
analysi revenu multipl analysi attribut platform rest net cash deriv platform valu estim potenti
market opportun huntington diseas hd duchenn muscular dystrophi dmd frontotempor dementia ftd amyotroph later
sclerosi al potenti sale valu collabor assum probabilities-of-success dcf appli
discount rate termin growth rate former high end biotech coverag account heighten risk
associ earli stage novel technolog revenu multipl analysi use multipl adjust product revenu slightli
higher compani coverag nbrv use reflect strong ip runway potenti superior
orphan drug margin recent acquisit rptp current sale offer orphan drug busi comp discount back use fulli
dilut share count includ outstand seri prefer share stock option
risk valuat believ higher averag risk-invest biotech industri due earli stage novel technolog platform
face signific clinic regulatori risk sinc product candid current preclin develop like mani development stage
biopharma compani also face manufactur competit commerci regulatori safeti risk well intellectu properti risk also face
financ risk dilut current sharehold sinc believ compani cash flow-posit
valuat estim per share price target month base discount cash flow analysi appli discount rate
consist rate appli valu arri juno probabl success-adjust p/w revenu forecast termin growth
rate rest net cash
risk valuat earli stage development pipelin agent face high clinic regulatori develop risk well commerci competit risk
small-cap biotech compani also face execut risk financi risk compani may addit financ need turn cash flow
posit
valuat zfgn deriv per share valu zfgn use discount cash flow analysi discount rate termin growth rate
price target assum probabl approv lead risk adjust peak sale estim
risk valuat risk valuat includ disappoint clinic data regulatori setback dilut risk addit equiti offer commerci
shortfal occurr could impact stock significantli
valuat zlab valu zlab price target base dcf valuat assum discount rate probability-adjust
sale profit appli termin growth rate major revenu contribut come niraparib omadacyclin fugan
account price target assum probabl success po niraparib second-lin first-lin fourth-
line set respect po niraparib opportun breast cancer omadacyclin assum probabl cabp commun
acquir bacteri pneumonia absssi acute-bacteri skin skin-structur infect po fugan china rest world
respect unrisk-adjust dcf-base price target would
risk valuat risk zlab includ clinic commerci execut support mid late stage asset evolv competit dynam china
well chang regulatori environ neg impact sustain prefer provid statu exist today local chines
compani like zlab
valuat deriv price target base blend revenu multipl dcf analysi use probability-of-
success dravet util discount rate latter believ appropri level risk adjust compani
phase data similar aldr also use revenu multipl account high potenti margin counterbalanc life-cycl
uncertainti beyond orphan drug exclus protect assum patent extend exclus us year beyond orphan middl
rang coverag univers comp multipl includ akao
risk valuat risk invest includ potenti disappoint clinic data efficaci safeti regulatori setback
commerci shortfal recent announc posit phase result first pivot trial howev assum success two studi requir
approv also believ need gener addit long term safeti data given histori fenfluramin obes show
cardiac advers event signal final investor also face dilut risk could impact stock significantli
